Thomas Jefferson University

Neal Shore

TitleVolunteer Faculty
InstitutionThomas Jefferson University
DepartmentFaculty Records and Publicatio - Thomas Jefferson University
Address833 Chestnut Street
Philadelphia PA 19023
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Beer TM, George DJ, Shore ND, Winters-Stone K, Wefel JS, Verholen F, Srinivasan S, Ortiz J, Morgans AK. Functional assessment in patients with castration-resistant prostate cancer treated with darolutamide: results from the DaroAcT study. Oncologist. 2025 Jul 04; 30(7). PMID: 39450762.
      Citations:    
    2. Shore ND, Antonarakis ES, Ross AE, Marshall CH, Stratton KL, Ayanambakkam A, Cookson MS, McKay RR, Bryce AH, Kaymakcalan MD. Correction: A multidisciplinary approach to address unmet needs in the management of patients with non-metastatic castration-resistant prostate cancer. Prostate Cancer Prostatic Dis. 2025 Jun; 28(2):529. PMID: 38643308.
      Citations:    
    3. Copelan O, Moss J, Freedman S, Coutinho K, Elterman D, Marotte J, Padron O, Shore N, Spier J, Kaminetsky J, Mazzarella B, Te A, Kaplan SA, McVary KT. Preservation of sexual function with Optilume-a novel treatment for lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Sex Med. 2025 04 08; 22(3):446-453. PMID: 39829245.
      Citations:    
    4. Freedland SJ, Mulhall JP, Gleave M, De Giorgi U, Saad F, Rannikko A, Ivanova JI, Nasr AF, Reisman AL, Ganguli A, Kral P, Turnbull J, Shore N. Effects of Enzalutamide on the Sexual Activity of Patients with Biochemically Recurrent Prostate Cancer: A Post Hoc Analysis of Patient-reported Outcomes in the EMBARK Study. Eur Urol. 2025 05; 87(5):507-511. PMID: 40016055.
      Citations:    
    5. Shore N. Reply: Clinician-Reported Management Recommendations in Response to Universal Germline Genetic Testing in Patients With Prostate Cancer. J Urol. 2025 May; 213(5):649-650. PMID: 39927589.
      Citations:    
    6. Shore N, Armstrong AJ, Barata P, Byrne L, Hafron J, Young S, Paller C, Wise DR, Ventii K, Samadi A, Arangua P, Werahera PN, Lorentz J. Implementing and Optimizing Universal Germline Genetic Testing for Patients With Prostate Cancer in Clinical Practice. Urology. 2025 05; 199:1-10. PMID: 39909130.
      Citations:    
    7. Daneshmand S, Kamat AM, Shore ND, Meeks JJ, Galsky MD, Jacob JM, van der Heijden MS, Williams SB, Powles T, Chang SS, Catto JWF, Psutka SP, Guerrero-Ramos F, Xylinas E, Miyake M, Simone G, Daniel K, Sweiti H, Cutie C, Necchi A. Development of TAR-200: A novel targeted releasing system designed to provide sustained delivery of gemcitabine for patients with bladder cancer. Urol Oncol. 2025 05; 43(5):286-296. PMID: 39818460.
      Citations:    
    8. Downs TM, Bailey HH, Lozar T, Schmitz NS, Green H, Scarlett CO, Havighurst TC, Twaroski K, DeShong K, Wollmer B, Bivalacqua TJ, Saltzstein DR, Shore N, Kim K, Huang W, Ricke WA, Barroilhet L, House M, Parnes HL, Messing E. Phase II Clinical Chemoprevention Trial of Weekly Erlotinib before Bladder Cancer Surgery. Cancer Prev Res (Phila). 2025 Jan 06; 18(1):31-39. PMID: 39187984.
      Citations:    
    9. Shore N, Nielsen SM, Esplin ED, Antonarakis ES, Barata PC, Beer TM, Beltran H, Bryce A, Cookson MS, Crawford ED, Dorff TB, George DJ, Heath EI, Helfand BT, Hussain M, Mckay RR, Morgans AK, Morris MJ, Paller CJ, Ross AE, Sartor O, Shen J, Sieber P, Smith MR, Wise DR, Armstrong AJ. Implementation of Universal Germline Genetic Testing Into Standard of Care for Patients With Prostate Cancer: The Time Is Now. JCO Oncol Pract. 2025 Jun; 21(6):747-753. PMID: 39700441.
      Citations:    
    10. Freedland SJ, Gleave M, De Giorgi U, Rannikko A, Pieczonka CM, Tutrone RF, Venugopal B, Woo HH, Ramirez-Backhaus M, Tarazi J, Tang Y, Ganguli A, Haas GP, Shore ND. Plain language summary: does enzalutamide treatment with or without leuprolide improve outcomes and affect quality of life in patients with high-risk biochemical recurrence? Future Oncol. 2025 Feb; 21(5):501-514. PMID: 39667819.
      Citations:    
    11. Bryce AH, Agarwal N, Beltran H, Hussain MH, Sartor O, Shore N, Antonarakis ES, Armstrong AJ, Calais J, Carducci MA, Dorff TB, Efstathiou JA, Gleave M, Gomella LG, Higano C, Hope TA, Iagaru A, Morgans AK, Morris DS, Morris MJ, Petrylak DP, Reiter RE, Rettig MB, Ryan CJ, Sellinger SB, Spratt DE, Srinivas S, Tagawa ST, Taplin ME, Yu EY, Zhang T, McKay RR, Koo PJ, Crawford ED. Implementing evidence-based strategies for men with biochemically recurrent and advanced prostate cancer: Consensus recommendations from the US Prostate Cancer Conference 2024. Cancer. 2025 Jan 01; 131(1):e35612. PMID: 39616467.
      Citations:    
    12. Shore N. Incorporating PSMA PET imaging into the treatment plan for newly diagnosed and recurrent prostate cancer. Clin Adv Hematol Oncol. 2024 Dec; 22(10):497-499. PMID: 39820373.
      Citations:    
    13. Shore ND, Cookson MS, Efstathiou E. The landscape of androgen deprivation therapies for the treatment of advanced prostate cancer. Future Oncol. 2024 Dec; 20(40):3351-3354. PMID: 39555581.
      Citations:    
    14. Shore ND, Morgans AK, Tutrone RF. Testosterone recovery post discontinuation of androgen deprivation for the treatment of advanced prostate cancer. Future Oncol. 2024 Dec; 20(39):3179-3182. PMID: 39555576.
      Citations:    
    15. La Cerda J, Thorley J, Sieber P, Cookson MS, Flanders SC, Gatoulis SC, Shore ND. Plain language review: the safety of relugolix combination therapy for advanced prostate cancer. Future Oncol. 2025 Jan; 21(1):51-62. PMID: 39503549.
      Citations:    
    16. Shore N, Brown G, Lowentritt B, O'Donnell L, Wilt W, Burbage S, Khilfeh I, Gaylis F. Evaluating the Importance of Practice-level Factors on Adherence to Prostate Cancer Treatment Guidelines in Urology. Urology. 2025 02; 196:147-154. PMID: 39489383.
      Citations:    
    17. Shore N, Carles J, McDermott R, Agarwal N, Tombal B. Treatment intensification with radium-223 plus enzalutamide in patients with metastatic castration-resistant prostate cancer. Front Med (Lausanne). 2024; 11:1460212. PMID: 39526247.
      Citations:    
    18. Azad AA, Fizazi K, Matsubara N, Saad F, De Giorgi U, Joung JY, Fong PCC, Jones RJ, Zsch?bitz S, Oldenburg J, Shore ND, Dunshee C, Carles J, Fay AP, Lin X, DeAnnuntis L, Di Santo N, Zielinski MA, Agarwal N. Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: Safety analyses from the randomized, placebo-controlled, phase III TALAPRO-2 study. Eur J Cancer. 2024 Dec; 213:115078. PMID: 39486165.
      Citations:    
    19. McManus HD, Dorff T, Morgans AK, Sartor O, Shore N, Armstrong AJ. Navigating therapeutic sequencing in the metastatic castration-resistant prostate cancer patient journey. Prostate Cancer Prostatic Dis. 2025 Sep; 28(3):672-683. PMID: 39420184.
      Citations:    
    20. Gillessen S, Turco F, Davis ID, Efstathiou JA, Fizazi K, James ND, Shore N, Small E, Smith M, Sweeney CJ, Tombal B, Zilli T, Agarwal N, Antonarakis ES, Aparicio A, Armstrong AJ, Bastos DA, Attard G, Axcrona K, Ayadi M, Beltran H, Bjartell A, Blanchard P, Bourlon MT, Briganti A, Bulbul M, Buttigliero C, Caffo O, Castellano D, Castro E, Cheng HH, Chi KN, Clarke CS, Clarke N, de Bono JS, De Santis M, Duran I, Efstathiou E, Ekeke ON, El Nahas TIH, Emmett L, Fanti S, Fatiregun OA, Feng FY, Fong PCC, Fonteyne V, Fossati N, George DJ, Gleave ME, Gravis G, Halabi S, Heinrich D, Herrmann K, Hofman MS, Hope TA, Horvath LG, Hussain MHA, Jereczek-Fossa BA, Jones RJ, Joshua AM, Kanesvaran R, Keizman D, Khauli RB, Kramer G, Loeb S, Mahal BA, Maluf FC, Mateo J, Matheson D, Matikainen MP, McDermott R, McKay RR, Mehra N, Merseburger AS, Morgans AK, Morris MJ, Mrabti H, Mukherji D, Murphy DG, Murthy V, Mutambirwa SBA, Nguyen PL, Oh WK, Ost P, O'Sullivan JM, Padhani AR, Parker C, Poon DMC, Pritchard CC, Rabah DM, Rathkopf D, Reiter RE, Renard-Penna R, Ryan CJ, Saad F, Sade JP, Sandhu S, Sartor OA, Schaeffer E, Scher HI, Sharifi N, Skoneczna IA, Soule HR, Spratt DE, Srinivas S, Sternberg CN, Suzuki H, Taplin ME, Thellenberg-Karlsson C, Tilki D, T?rkeri LN, Uemura H, ?r?n Y, Vale CL, Vapiwala N, Walz J, Yamoah K, Ye D, Yu EY, Zapatero A, Omlin A. Management of Patients with Advanced Prostate Cancer. Report from the 2024 Advanced Prostate Cancer Consensus Conference (APCCC). Eur Urol. 2025 Feb; 87(2):157-216. PMID: 39394013.
      Citations:    
    21. Clarke NW, Armstrong AJ, Oya M, Shore N, Procopio G, Daniel Guedes J, Arslan C, Mehra N, Parnis F, Brown E, Schl?rmann F, Young Joung J, Sugimoto M, Sartor O, Poehlein C, McGuinness D, Degboe A, Saad F. Efficacy and Safety of Olaparib Plus Abiraterone Versus Placebo Plus Abiraterone in the First-line Treatment of Patients with Asymptomatic/Mildly Symptomatic and Symptomatic Metastatic Castration-resistant Prostate Cancer: Analyses from the Phase 3 PROpel Trial. Eur Urol Oncol. 2025 Apr; 8(2):394-406. PMID: 39384451.
      Citations:    
    22. Saad F, Vjaters E, Shore N, Olmos D, Xing N, Pereira de Santana Gomes AJ, Cesar de Andrade Mota A, Salman P, Jievaltas M, Ulys A, Jakubovskis M, Kopyltsov E, Han W, Nevalaita L, Testa I, Le Berre MA, Kuss I, Haresh KP. Darolutamide in Combination With Androgen-Deprivation Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer From the Phase III ARANOTE Trial. J Clin Oncol. 2024 Dec 20; 42(36):4271-4281. PMID: 39279580.
      Citations:    
    23. Morris MJ, Castellano D, Herrmann K, de Bono JS, Shore ND, Chi KN, Crosby M, Piulats JM, Fl?chon A, Wei XX, Mahammedi H, Roubaud G, ?tudentov? H, Nagarajah J, Mellado B, Montesa-Pino ?, Kpamegan E, Ghebremariam S, Kreisl TN, Wilke C, Lehnhoff K, Sartor O, Fizazi K. 177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial. Lancet. 2024 09 28; 404(10459):1227-1239. PMID: 39293462.
      Citations:    
    24. Shore N, Pieczonka C, Heron S, Gazi M, Cahn D, Belkoff LH, Berger A, Mazzarella B, Veys J, Idom C, Morris D, Jayram G, Engelman A, Dato P, Bevan-Thomas R, Wise DR, Hardwick MK, Rojahn S, Layman P, Heald B, Ellsworth RE, Hatchell KE, Nussbaum RL, Nielsen SM, Esplin ED. Reply by Authors. J Urol. 2024 Dec; 212(6):842-843. PMID: 39226588.
      Citations:    
    25. Shore ND, De Giorgi U, Freedland SJ. Enzalutamide in Men With High-Risk Biochemically Recurrent Prostate Cancer: Rationale and Treatment Considerations From EMBARK. J Urol. 2025 Jan; 213(1):110-113. PMID: 39226589.
      Citations:    
    26. Shore N, Pieczonka C, Heron S, Gazi M, Cahn D, Belkoff LH, Berger A, Mazzarella B, Veys J, Idom C, Morris D, Jayram G, Engelman A, Dato P, Bevan-Thomas R, Wise DR, Hardwick MK, Rojahn S, Layman P, Heald B, Ellsworth RE, Hatchell KE, Nussbaum RL, Nielsen SM, Esplin ED. Clinician-Reported Management Recommendations in Response to Universal Germline Genetic Testing in Patients With Prostate Cancer. J Urol. 2024 12; 212(6):832-843. PMID: 39121056.
      Citations:    
    27. Shore N, Hafron J, Saltzstein D, Brown G, Belkoff L, Aggarwal P, Phillips J, Bhaumik A, McGowan T. Apalutamide for High-Risk Localized Prostate Cancer Following Radical Prostatectomy (Apa-RP). J Urol. 2024 11; 212(5):682-691. PMID: 39088398.
      Citations:    
    28. George DJ, Morgans AK, Constantinovici N, Khan N, Khan J, Chen G, Hlebec V, Shore ND. Androgen Receptor Inhibitors in Patients With Nonmetastatic Castration-Resistant Prostate Cancer. JAMA Netw Open. 2024 08 01; 7(8):e2429783. PMID: 39190308.
      Citations:    
    29. Agarwal N, Saad F, Azad AA, Mateo J, Matsubara N, Shore ND, Chakrabarti J, Chen HC, Lanzalone S, Niyazov A, Fizazi K. The TALAPRO-3 study design: a plain language summary. Future Oncol. 2024; 20(30):2225-2231. PMID: 39451095.
      Citations:    
    30. Agarwal N, Azad AA, Carles J, Fay AP, Matsubara N, Heinrich D, Szczylik C, De Giorgi U, Joung JY, Fong PCC, Voog E, Jones RJ, Shore ND, Dunshee C, Zsch?bitz S, Oldenburg J, Lin X, Healy CG, Di Santo N, Zohren F, Fizazi K. Plain language summary of the results from the TALAPRO-2 study: Talazoparib plus enzalutamide versus placebo plus enzalutamide for patients with advanced prostate cancer. Future Oncol. 2024; 20(29):2123-2135. PMID: 38995237.
      Citations:    
    31. Shore N, Hafron J, Saltzstein D, Bhaumik A, Aggarwal P, Phillips J, McGowan T. Impact of a rash management guide in patients receiving apalutamide for high-risk localized prostate cancer in the Apa-RP study. Prostate Cancer Prostatic Dis. 2025 Sep; 28(3):828-831. PMID: 38969791.
      Citations:    
    32. Shore ND, Gratzke C, Feyerabend S, Werbrouck P, Carles J, Vjaters E, Tammela TLJ, Morris D, Aragon-Ching JB, Concepcion RS, Emmenegger U, Fleshner N, Grabbert M, Lietuvietis V, Mahammedi H, Cruz FM, Paula A, Pieczonka C, Rannikko A, Richardet M, Silveira G, Kuss I, Le Berre MA, Verholen F, Sarapohja T, Smith MR, Fizazi K. Extended Safety and Tolerability of Darolutamide for Nonmetastatic Castration-Resistant Prostate Cancer and Adverse Event Time Course in ARAMIS. Oncologist. 2024 07 05; 29(7):581-588. PMID: 38394384.
      Citations:    
    33. Shore ND, Broder MS, Barata PC, Crispino T, Fay AP, Lloyd J, Mellado B, Matsubara N, Pfanzelter N, Schlack K, Sieber P, Soares A, Dalglish H, Niyazov A, Shaman S, Zielinski MA, Chang J, Agarwal N. Expert Consensus Recommendations on the Management of Treatment-emergent Adverse Events Among Men with Prostate Cancer Taking Poly-ADP Ribose Polymerase Inhibitor + Novel Hormonal Therapy Combination Therapy. Eur Urol Oncol. 2025 Feb; 8(1):94-104. PMID: 38866640.
      Citations:    
    34. Moul JW, Shore ND, Pienta KJ, Czernin J, King MT, Freedland SJ. Correction: Application of next-generation imaging in biochemically recurrent prostate cancer. Prostate Cancer Prostatic Dis. 2024 Jun; 27(2):358. PMID: 38233472.
      Citations:    
    35. Hussain M, Fizazi K, Shore ND, Heidegger I, Smith MR, Tombal B, Saad F. Metastatic Hormone-Sensitive Prostate Cancer and Combination Treatment Outcomes: A Review. JAMA Oncol. 2024 06 01; 10(6):807-820. PMID: 38722620.
      Citations:    
    36. Morgans AK, Grossman JP, Paracha N, Ladino D, Tyas E, Rodriguez-Santamaria F, Shore N. Within-trial hospitalization resource utilization and budget impact analysis for darolutamide in metastatic hormone-sensitive prostate cancer using ARASENS. J Manag Care Spec Pharm. 2024 Sep; 30(9):991-1000. PMID: 38807035.
      Citations:    
    37. Abou Chakra M, Shore ND, Brown ES, Du GJ, O'Donnell MA. Establishing an Intravesical Doublet Chemotherapy Clinic for Nonmuscle-Invasive Bladder Cancer Patients. Urol Pract. 2024 07; 11(4):613-623. PMID: 38899680.
      Citations:    
    38. Weiner AB, Kakani P, Armstrong AJ, Bossi A, Cornford P, Feng F, Kanabur P, Karnes RJ, Mckay RR, Morgan TM, Schaeffer EM, Shore N, Tree AC, Spratt DE. Risk Stratification of Patients with Recurrence After Primary Treatment for Prostate Cancer: A Systematic Review. Eur Urol. 2024 Sep; 86(3):200-210. PMID: 38782697.
      Citations:    
    39. Sannala CKR, MacLean C, Larsen F, van Os S, Jadhav P, Shore N, Morgans AK, Okwuosa T, Gobburu J. A Model-Informed Drug Development Approach to Design a Phase 3 Trial of Teverelix Drug Product in Advanced Prostate Cancer Patients with Increased Cardiovascular Risk. Clin Pharmacol Drug Dev. 2024 Aug; 13(8):915-929. PMID: 38757461.
      Citations:    
    40. Necchi A, Roumigui? M, Kamat AM, Shore ND, Boormans JL, Esen AA, Lebret T, Kandori S, Bajorin DF, Krieger LEM, Niglio SA, Uchio EM, Seo HK, de Wit R, Singer EA, Grivas P, Nishiyama H, Li H, Baranwal P, Van den Sigtenhorst-Fijlstra M, Kapadia E, Kulkarni GS. Pembrolizumab monotherapy for high-risk non-muscle-invasive bladder cancer without carcinoma in situ and unresponsive to BCG (KEYNOTE-057): a single-arm, multicentre, phase 2 trial. Lancet Oncol. 2024 06; 25(6):720-730. PMID: 38740030.
      Citations:    
    41. Lotan Y, Daneshmand S, Shore N, Black P, Scarpato KR, Patel A, Lough T, Shoskes DA, Raman JD. Reply by Authors. J Urol. 2024 07; 212(1):50-51. PMID: 38728316.
      Citations:    
    42. Narayan VM, Boorjian SA, Alemozaffar M, Konety BR, Shore ND, Gomella LG, Kamat AM, Bivalacqua TJ, Montgomery JS, Lerner SP, Busby JE, Poch M, Crispen PL, Steinberg GD, Schuckman AK, Downs TM, Mashni J, Lane BR, Guzzo TJ, Bratslavsky G, Karsh LI, Woods ME, Brown G, Canter D, Luchey A, Lotan Y, Inman BA, Williams MB, Cookson MS, Chang SS, Sankin AI, O'Donnell MA, Sawutz D, Philipson R, Parker NR, Yla-Herttuala S, Rehm D, Jakobsen JS, Juul K, Dinney CPN. Efficacy of Intravesical Nadofaragene Firadenovec for Patients With Bacillus Calmette-Gu?rin-Unresponsive Nonmuscle-Invasive Bladder Cancer: 5-Year Follow-Up From a Phase 3 Trial. J Urol. 2024 07; 212(1):74-86. PMID: 38704840.
      Citations:    
    43. Lotan Y, Daneshmand S, Shore N, Black P, Scarpato KR, Patel A, Lough T, Shoskes DA, Raman JD. A Multicenter Prospective Randomized Controlled Trial Comparing Cxbladder Triage to Cystoscopy in Patients With Microhematuria: The Safe Testing of Risk for Asymptomatic Microhematuria Trial. J Urol. 2024 07; 212(1):41-51. PMID: 38700731.
      Citations:    
    44. Spratt DE, George DJ, Shore ND, Cookson MS, Saltzstein DR, Tutrone R, Bossi A, Brown BA, Lu S, Fallick M, Hanson S, Tombal BF. Efficacy and Safety of Radiotherapy Plus Relugolix in Men With Localized or Advanced Prostate Cancer. JAMA Oncol. 2024 05 01; 10(5):594-602. PMID: 38451492.
      Citations:    
    45. Fizazi K, Azad AA, Matsubara N, Carles J, Fay AP, De Giorgi U, Joung JY, Fong PCC, Voog E, Jones RJ, Shore ND, Dunshee C, Zsch?bitz S, Oldenburg J, Ye D, Lin X, Healy CG, Di Santo N, Laird AD, Zohren F, Agarwal N. Publisher Correction: First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial. Nat Med. 2024 May; 30(5):1505. PMID: 38297094.
      Citations:    
    46. Karsh L, Du S, He J, Waters D, Muser E, Shore N. Differences in real-world outcomes by risk classification for localized prostate cancer patients after radiation therapy. Prostate. 2024 Aug; 84(11):1047-1055. PMID: 38685667.
      Citations:    
    47. Saad F, Hussain MHA, Tombal B, Fizazi K, Sternberg CN, Crawford ED, Nordquist LT, B?gemann M, Tutrone R, Shore ND, Belkoff L, Fralich T, Jhaveri J, Srinivasan S, Li R, Verholen F, Kuss I, Smith MR. Deep and Durable Prostate-specific Antigen Response to Darolutamide with Androgen Deprivation Therapy and Docetaxel, and Association with Clinical Outcomes for Patients with High- or Low-volume Metastatic Hormone-sensitive Prostate Cancer: Analyses of the Randomized Phase 3 ARASENS Study. Eur Urol. 2024 Oct; 86(4):329-339. PMID: 38644146.
      Citations:    
    48. Crawford ED, Bryce AH, Hussain MH, Agarwal N, Beltran H, Cooperberg MR, Petrylak DP, Shore N, Spratt DE, Tagawa ST, Antonarakis ES, Aparicio AM, Armstrong AJ, Boike TP, Calais J, Carducci MA, Chapin BF, Cookson MS, Davis JW, Dorff T, Eggener SE, Feng FY, Gleave M, Higano C, Iagaru A, Morgans AK, Morris M, Murray KS, Poage W, Rettig MB, Sartor O, Scher HI, Sieber P, Small E, Srinivas S, Yu EY, Zhang T, Koo PJ. Expert Perspectives on Controversies in Castration-Sensitive Prostate Cancer Management: Narrative Review and Report of the First US Prostate Cancer Conference Part 1. JU Open Plus. 2024 Apr; 2(4). PMID: 38774466.
      Citations:    
    49. Bryce AH, Crawford ED, Agarwal N, Hussain MH, Beltran H, Cooperberg MR, Petrylak DP, Shore N, Spratt DE, Tagawa ST, Antonarakis ES, Aparicio AM, Armstrong AJ, Boike TP, Calais J, Carducci MA, Chapin BF, Cookson MS, Davis JW, Dorff T, Eggener SE, Feng FY, Gleave M, Higano C, Iagaru A, Morgans AK, Morris M, Murray KS, Poage W, Rettig MB, Sartor O, Scher HI, Sieber P, Small E, Srinivas S, Yu EY, Zhang T, Koo PJ. Expert Perspectives on Controversies in Metastatic Castration-Resistant Prostate Cancer Management: Narrative Review and Report of the First US Prostate Cancer Conference Part 2. JU Open Plus. 2024 Apr; 2(4). PMID: 38774467.
      Citations:    
    50. Ross AE, Iwata KK, Elsouda D, Hairston J, Russell D, Davicioni E, Proudfoot JA, Shore ND, Schaeffer EM. Transcriptome-Based Prognostic and Predictive Biomarker Analysis of ENACT: A Randomized Controlled Trial of Enzalutamide in Men Undergoing Active Surveillance. JCO Precis Oncol. 2024 Apr; 8:e2300603. PMID: 38635932.
      Citations:    
    51. McKay RR, Morgans AK, Shore ND, Dunshee C, Devgan G, Agarwal N. First-line combination treatment with PARP and androgen receptor-signaling inhibitors in HRR-deficient mCRPC: Applying clinical study findings to clinical practice in the United States. Cancer Treat Rev. 2024 May; 126:102726. PMID: 38613872.
      Citations:    
    52. Moussa M, Abou Chakra M, Shore ND, Papatsoris A, Farahat Y, O'Donnell MA. Patterns of treatment of high-risk BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) patients among Arab urologists. Arch Ital Urol Androl. 2024 Mar 19; 96(1):12244. PMID: 38502039.
      Citations:    
    53. Narayan VM, Meeks JJ, Jakobsen JS, Shore ND, Sant GR, Konety BR. Mechanism of action of nadofaragene firadenovec-vncg. Front Oncol. 2024; 14:1359725. PMID: 38559556.
      Citations:    
    54. Abida W, Hahn AW, Shore N, Agarwal N, Sieber P, Smith MR, Dorff T, Monk P, Rettig M, Patel R, Page A, Duff M, Xu R, Wang J, Barkund S, Pankov A, Wang A, Junttila MR, Multani PS, Daemen A, Chow Maneval E, Logothetis CJ, Morris MJ. Phase I Study of ORIC-101, a Glucocorticoid Receptor Antagonist, in Combination with Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer Progressing on Enzalutamide. Clin Cancer Res. 2024 03 15; 30(6):1111-1120. PMID: 38226958.
      Citations:    
    55. Vaishampayan UN, Keessen M, Dreicer R, Heath EI, Buchler T, ?rkosy PF, Cs?szi T, Wiechno P, Kopyltsov E, Orlov SV, Plekhanov A, Smagina M, Varlamov S, Shore ND. A global phase II randomized trial comparing oral taxane ModraDoc006/r to intravenous docetaxel in metastatic castration resistant prostate cancer. Eur J Cancer. 2024 May; 202:114007. PMID: 38518534.
      Citations:    
    56. Shore ND, Hussain M, Saad F, Fizazi K, Sternberg CN, Crawford D, Tombal B, Nordquist L, Cookson M, Verholen F, Jhaveri J, Srinivasan S, Smith MR. Efficacy and Safety of Darolutamide in Combination With Androgen-Deprivation Therapy and Docetaxel in Black Patients From the Randomized ARASENS Trial. Oncologist. 2024 03 04; 29(3):235-243. PMID: 37812679.
      Citations:    
    57. Grajales V, Martini A, Shore ND. Complications of immuno-oncology care: what urologist should know. BJU Int. 2024 05; 133(5):524-531. PMID: 38437876.
      Citations:    
    58. Shore ND, Antonarakis ES, Ross AE, Marshall CH, Stratton KL, Ayanambakkam A, Cookson MS, McKay RR, Bryce AH, Kaymakcalan MD. A multidisciplinary approach to address unmet needs in the management of patients with non-metastatic castration-resistant prostate cancer. Prostate Cancer Prostatic Dis. 2025 Jun; 28(2):250-259. PMID: 38431761.
      Citations:    
    59. Steinberg GD, Shore ND, Redorta JP, Galsky MD, Bedke J, Ku JH, Kretkowski M, Hu H, Penkov K, Vermette JJ, Tarazi JC, Randall AE, Pierce KJ, Saltzstein D, Powles TB. CREST: phase III study of sasanlimab and Bacillus Calmette-Gu?rin for patients with Bacillus Calmette-Gu?rin-na?ve high-risk non-muscle-invasive bladder cancer. Future Oncol. 2024 May; 20(14):891-901. PMID: 38189180.
      Citations:    
    60. Shore ND, Tarazi J, Freedland SJ. Enzalutamide in Biochemically Recurrent Prostate Cancer. Reply. N Engl J Med. 2024 01 04; 390(1):90-91. PMID: 38169498.
      Citations:    
    61. Cooley LF, Srivastava A, Shore ND. Updates on Management of Biochemical Recurrent Prostate Cancer. Curr Treat Options Oncol. 2024 03; 25(3):284-292. PMID: 38286895.
      Citations:    
    62. Tutrone R, Saad F, George DJ, Tombal B, Bailen JL, Cookson MS, Saltzstein DR, Hanson S, Brown B, Lu S, Fallick M, Shore ND. Testosterone Recovery for Relugolix Versus Leuprolide in Men with Advanced Prostate Cancer: Results from the Phase 3 HERO Study. Eur Urol Oncol. 2024 Aug; 7(4):906-913. PMID: 38143206.
      Citations:    
    63. Lotan Y, Barocas DA, Chang SS, Daneshmand S, Konety B, Meeks JJ, Porten S, Raman JD, Rosser CJ, Scarpato KR, Sexton WJ, Sfakianos JP, Shore ND, Svatek RS. Commentary on Novitas LCD. Bladder Cancer. 2023; 9(4):305-312. PMID: 38994243.
      Citations:    
    64. Gore JL, Follmer K, Reynolds J, Nash M, Anderson CB, Catto JWF, Chamie K, Daneshmand S, Dickstein R, Garg T, Gilbert SM, Guzzo TJ, Kamat AM, Kates MR, Lane BR, Lotan Y, Mansour AM, Master VA, Montgomery JS, Morris DS, Nepple KG, O'Neil BB, Patel S, Pohar K, Porten SP, Riggs SB, Sankin A, Scarpato KR, Shore ND, Steinberg GD, Strope SA, Taylor JM, Comstock BA, Kessler LG, Wolff EM, Smith AB. Interruptions in bladder cancer care during the COVID-19 public health emergency. Urol Oncol. 2024 04; 42(4):116.e17-116.e21. PMID: 38087711.
      Citations:    
    65. Gomez-Veiga F, Szmulewitz RZ, Holzbeierlein J, Azad AA, Iguchi T, Villers A, Alcaraz A, Alekseev B, Shore ND, Rosbrook B, Zohren F, Ma J, Haas GP, Stenzl A, Armstrong AJ. Clinical Outcomes of Enzalutamide in Metastatic Hormone-sensitive Prostate Cancer in Patients Aged <75 and =75 Years: ARCHES Post Hoc Analysis. Eur Urol Oncol. 2024 Aug; 7(4):860-869. PMID: 38072761.
      Citations:    
    66. Fizazi K, Azad AA, Matsubara N, Carles J, Fay AP, De Giorgi U, Joung JY, Fong PCC, Voog E, Jones RJ, Shore ND, Dunshee C, Zsch?bitz S, Oldenburg J, Ye D, Lin X, Healy CG, Di Santo N, Laird AD, Zohren F, Agarwal N. First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial. Nat Med. 2024 01; 30(1):257-264. PMID: 38049622.
      Citations:    
    67. Mateo J, de Bono JS, Fizazi K, Saad F, Shore N, Sandhu S, Chi KN, Agarwal N, Olmos D, Thiery-Vuillemin A, ?zg?roglu M, Mehra N, Matsubara N, Young Joung J, Padua C, Korbenfeld E, Kang J, Marshall H, Lai Z, Barnicle A, Poehlein C, Lukashchuk N, Hussain M. Olaparib for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer and Alterations in BRCA1 and/or BRCA2 in the PROfound Trial. J Clin Oncol. 2024 Feb 10; 42(5):571-583. PMID: 37963304.
      Citations:    
    68. Yu EY, Berry WR, Gurney H, Retz M, Conter HJ, Laguerre B, Fong PCC, Ferrario C, Todenh?fer T, Gravis G, Piulats JM, Emmenegger U, Shore ND, Romano E, Mourey L, Li XT, Poehlein CH, Schloss C, Appleman LJ, de Bono JS. Pembrolizumab and Enzalutamide in Patients with Abiraterone Acetate-Pretreated Metastatic Castration-Resistant Prostate Cancer: Cohort C of the Phase 1b/2 KEYNOTE-365 Study. Eur Urol Oncol. 2024 Jun; 7(3):509-518. PMID: 37940446.
      Citations:    
    69. Abou Chakra M, Shore ND, Dillon R, O'Donnell MA. US Clinical Practice Patterns of Intravesical Chemotherapy for Bacillus Calmette-Gu?rin-Unresponsive and Bacillus Calmette-Gu?rin-Exposed Nonmuscle-Invasive Bladder Cancer. Urol Pract. 2024 01; 11(1):97-107. PMID: 37903746.
      Citations:    
    70. Jones RH, Fizazi K, James ND, Tammela TL, Matsubara N, Priou F, Beuzeboc P, Lesimple T, Bono P, Kataja V, Garcia JA, Protheroe A, Shore N, Aspegren J, Joensuu H, Kuss I, Fiala-Buskies S, Vjaters E. Safety and tolerability of long-term treatment with darolutamide in patients with metastatic castration-resistant prostate cancer. Prostate Cancer Prostatic Dis. 2024 Dec; 27(4):786-789. PMID: 37884613.
      Citations:    
    71. Agarwal N, Saad F, Azad AA, Mateo J, Matsubara N, Shore ND, Chakrabarti J, Chen HC, Lanzalone S, Niyazov A, Fizazi K. TALAPRO-3 clinical trial protocol: phase III study of talazoparib plus enzalutamide in metastatic castration-sensitive prostate cancer. Future Oncol. 2024 Mar; 20(9):493-505. PMID: 37882449.
      Citations:    
    72. Freedland SJ, Gleave M, De Giorgi U, Rannikko A, Pieczonka CM, Tutrone RF, Venugopal B, Woo HH, Ramirez-Backhaus M, Supiot S, Lantz A, Ganguli A, Ivanova J, Kral P, Huang SP, Saad F, Shore ND. Enzalutamide and Quality of Life in Biochemically Recurrent Prostate Cancer. NEJM Evid. 2023 12; 2(12):EVIDoa2300251. PMID: 38320501.
      Citations:    
    73. Freedland SJ, de Almeida Luz M, De Giorgi U, Gleave M, Gotto GT, Pieczonka CM, Haas GP, Kim CS, Ramirez-Backhaus M, Rannikko A, Tarazi J, Sridharan S, Sugg J, Tang Y, Tutrone RF, Venugopal B, Villers A, Woo HH, Zohren F, Shore ND. Improved Outcomes with Enzalutamide in Biochemically Recurrent Prostate Cancer. N Engl J Med. 2023 10 19; 389(16):1453-1465. PMID: 37851874.
      Citations:    
    74. Tombal B, Collins S, Morgans AK, Hunsche E, Brown B, Zhu E, Bossi A, Shore N. Impact of Relugolix Versus Leuprolide on the Quality of Life of Men with Advanced Prostate Cancer: Results from the Phase 3 HERO Study. Eur Urol. 2023 12; 84(6):579-587. PMID: 37833178.
      Citations:    
    75. Saad F, George DJ, Cookson MS, Saltzstein DR, Tutrone R, Bossi A, Brown B, Selby B, Lu S, Tombal B, Shore ND. Relugolix vs. Leuprolide Effects on Castration Resistance-Free Survival from the Phase 3 HERO Study in Men with Advanced Prostate Cancer. Cancers (Basel). 2023 Oct 05; 15(19). PMID: 37835548.
      Citations:    
    76. Mossanen M, Smith AB, Onochie N, Matulewicz R, Bjurlin MA, Kibel AS, Abbas M, Shore N, Chisolm S, Bangs R, Cooper Z, Gore JL. Bladder cancer patient and provider perspectives on smoking cessation. Urol Oncol. 2023 11; 41(11):457.e9-457.e16. PMID: 37805339.
      Citations:    
    77. Kamat AM, Apolo AB, Babjuk M, Bivalacqua TJ, Black PC, Buckley R, Campbell MT, Comp?rat E, Efstathiou JA, Grivas P, Gupta S, Kurtz NJ, Lamm D, Lerner SP, Li R, McConkey DJ, Palou Redorta J, Powles T, Psutka SP, Shore N, Steinberg GD, Sylvester R, Witjes JA, Galsky MD. Definitions, End Points, and Clinical Trial Designs for Bladder Cancer: Recommendations From the Society for Immunotherapy of Cancer and the International Bladder Cancer Group. J Clin Oncol. 2023 12 10; 41(35):5437-5447. PMID: 37793077.
      Citations:    
    78. Efstathiou JA, Morgans AK, Bland CS, Shore ND. Novel hormone therapy and coordination of care in high-risk biochemically recurrent prostate cancer. Cancer Treat Rev. 2024 Jan; 122:102630. PMID: 38035646.
      Citations:    
    79. Shore N, Scott TA, Srivastava A, Grove R, Thompson A, Tierno MB, Haberberger J. Influencing Best Practices for Genomic and Germline Testing in Urology. Urol Pract. 2023 Nov; 10(6):648-654. PMID: 37647173.
      Citations:    
    80. Chang E, Hahn NM, Lerner SP, Fallah J, Agrawal S, Kamat AM, Bhatnagar V, Svatek RS, Jaigirdar AA, Bross P, Shore N, Kates M, Sachse K, Brewer JR, O'Donnell MA, Steinberg GD, Viviano CJ, Bloomquist E, Ribal MJ, Galsky MD, Oliver R, Black PC, Al-Ahmadie H, Brothers K, Pohar K, Dinney CP, Feng Z, Downs TM, Porten SP, Smith AB, Bangs R, Psutka SP, Agarwal N, Amiri-Kordestani L, Suzman DL, Pazdur R, Kluetz PG, Weinstock C. Advancing Clinical Trial Design for Non-Muscle Invasive Bladder Cancer. Bladder Cancer. 2023; 9(3):271-286. PMID: 38993184.
      Citations:    
    81. Shore ND, Polikarpov DM, Pieczonka CM, Henderson RJ, Bailen JL, Saltzstein DR, Concepcion RS, Beebe-Dimmer JL, Ruterbusch JJ, Levin RA, Wissmueller S, Le TH, Gillatt DA, Chan DW, Deng N, Siddireddy JS, Lu Y, Campbell DH, Walsh BJ. Development and evaluation of the MiCheck? Prostate test for clinically significant prostate cancer. Urol Oncol. 2023 11; 41(11):454.e9-454.e16. PMID: 37734979.
      Citations:    
    82. Shore ND, Fizazi K, Tammela TLJ, Luz M, Salas MP, Ouellette P, Lago S, Bastos DA, Jansz GK, C?rcano FM, Andrade L, Pliskin M, Lazaretti N, Arruda L, Correa Ochoa JJ, Kuss I, Kappeler C, Sarapohja T, Smith M. Effect of crossover from placebo to darolutamide on overall survival in men with non-metastatic prostate cancer: sensitivity analyses from the randomised phase 3 ARAMIS study. Eur J Cancer. 2023 Sep 17; 195:113342. PMID: 39491396.
      Citations:    
    83. Shore ND, Mehlhaff BA, Cookson MS, Saltzstein DR, Tutrone R, Brown B, Lu S, Fallick M, Hanson S, Saad F. Impact of Concomitant Cardiovascular Therapies on Efficacy and Safety of Relugolix vs Leuprolide: Subgroup Analysis from HERO Study in Advanced Prostate Cancer. Adv Ther. 2023 11; 40(11):4919-4927. PMID: 37713020.
      Citations:    
    84. Saad F, Clarke NW, Oya M, Shore N, Procopio G, Guedes JD, Arslan C, Mehra N, Parnis F, Brown E, Schl?rmann F, Joung JY, Sugimoto M, Sartor O, Liu YZ, Poehlein C, Barker L, Del Rosario PM, Armstrong AJ. Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial. Lancet Oncol. 2023 10; 24(10):1094-1108. PMID: 37714168.
      Citations:    
    85. Moul JW, Shore ND, Pienta KJ, Czernin J, King MT, Freedland SJ. Application of next-generation imaging in biochemically recurrent prostate cancer. Prostate Cancer Prostatic Dis. 2024 Jun; 27(2):202-211. PMID: 37679601.
      Citations:    
    86. Shore ND, Moul JW, Pienta KJ, Czernin J, King MT, Freedland SJ. Biochemical recurrence in patients with prostate cancer after primary definitive therapy: treatment based on risk stratification. Prostate Cancer Prostatic Dis. 2024 Jun; 27(2):192-201. PMID: 37679602.
      Citations:    
    87. Shore N, Gazi M, Pieczonka C, Heron S, Modh R, Cahn D, Belkoff LH, Berger A, Mazzarella B, Veys J, Idom C, Morris D, Jayram G, Engelman A, Bukkapatnam R, Dato P, Bevan-Thomas R, Cornell R, Wise DR, Hardwick MK, Hernandez RD, Rojahn S, Layman P, Hatchell KE, Heald B, Nussbaum RL, Nielsen SM, Esplin ED. Efficacy of National Comprehensive Cancer Network Guidelines in Identifying Pathogenic Germline Variants Among Unselected Patients with Prostate Cancer: The PROCLAIM Trial. Eur Urol Oncol. 2023 10; 6(5):477-483. PMID: 37574391.
      Citations:    
    88. Hussain M, Sternberg CN, Efstathiou E, Fizazi K, Shen Q, Lin X, Sugg J, Steinberg J, Noerby B, Giorgi U, Shore ND, Saad F. Plain language summary: Can declines in prostate-specific antigen level indicate how long patients with advanced prostate cancer will live when treated with enzalutamide? Future Oncol. 2023 Sep; 19(29):1953-1960. PMID: 37585665.
      Citations:    
    89. Prasad SM, Huang WC, Shore ND, Hu B, Bjurlin M, Brown G, Genov P, Shishkov D, Khuskivadze A, Ganev T, Marchev D, Orlov I, Kopyltsov E, Zubarev V, Nosov A, Komlev D, Burger B, Raju S, Meads A, Schoenberg M. Treatment of Low-grade Intermediate-risk Nonmuscle-invasive Bladder Cancer With UGN-102 ? Transurethral Resection of Bladder Tumor Compared to Transurethral Resection of Bladder Tumor Monotherapy: A Randomized, Controlled, Phase 3 Trial (ATLAS). J Urol. 2023 10; 210(4):619-629. PMID: 37548555.
      Citations:    
    90. Nelson AJ, Lopes RD, Hong H, Hua K, Slovin S, Tan S, Nilsson J, Bhatt DL, Goodman SG, Evans CP, Clarke NW, Shore ND, Margel D, Klotz LH, Tombal B, Leong DP, Alexander JH, Higano CS. Cardiovascular Effects of GnRH Antagonists Compared With Agonists in?Prostate Cancer: A Systematic Review. JACC CardioOncol. 2023 Oct; 5(5):613-624. PMID: 37969642.
      Citations:    
    91. Fizazi K, Shore ND, Smith M, Ramos R, Jones R, Niegisch G, Vjaters E, Wang Y, Srinivasan S, Sarapohja T, Verholen F. Efficacy and safety outcomes of darolutamide in patients with non-metastatic castration-resistant prostate cancer with comorbidities and concomitant medications from the randomised phase 3 ARAMIS trial. Eur J Cancer. 2023 10; 192:113258. PMID: 37660438.
      Citations:    
    92. Antonarakis ES, Subudhi SK, Pieczonka CM, Karsh LI, Quinn DI, Hafron JM, Wilfehrt HM, Harmon M, Sheikh NA, Shore ND, Petrylak DP. Combination Treatment with Sipuleucel-T and Abiraterone Acetate or Enzalutamide for Metastatic Castration-Resistant Prostate Cancer: STAMP and STRIDE Trials. Clin Cancer Res. 2023 07 05; 29(13):2426-2434. PMID: 37058234.
      Citations:    
    93. Agarwal N, Azad AA, Carles J, Fay AP, Matsubara N, Heinrich D, Szczylik C, De Giorgi U, Young Joung J, Fong PCC, Voog E, Jones RJ, Shore ND, Dunshee C, Zsch?bitz S, Oldenburg J, Lin X, Healy CG, Di Santo N, Zohren F, Fizazi K. Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial. Lancet. 2023 07 22; 402(10398):291-303. PMID: 37285865.
      Citations:    
    94. Higano CS, George DJ, Shore ND, Sartor O, Miller K, Conti PS, Sternberg CN, Saad F, Sade JP, Bellmunt J, Smith MR, Chandrawansa K, Sandstr?m P, Verholen F, Tombal B. Clinical outcomes and treatment patterns in REASSURE: planned interim analysis of a real-world observational study of radium-223 in metastatic castration-resistant prostate cancer. EClinicalMedicine. 2023 Jun; 60:101993. PMID: 37251627.
      Citations:    
    95. Armstrong AJ, Iguchi T, Azad AA, Villers A, Alekseev B, Petrylak DP, Szmulewitz RZ, Alcaraz A, Shore ND, Holzbeierlein J, Gomez-Veiga F, Rosbrook B, Zohren F, Haas GP, Gourgiotti G, El-Chaar N, Stenzl A. The Efficacy of Enzalutamide plus Androgen Deprivation Therapy in Oligometastatic Hormone-sensitive Prostate Cancer: A Post Hoc Analysis of ARCHES. Eur Urol. 2023 08; 84(2):229-241. PMID: 37179240.
      Citations:    
    96. De La Cerda J, Dunshee C, Gervasi L, Sieber P, Belkoff L, Tutrone R, Lu S, Gatoulis SC, Brown B, Migoya E, Shore N. A Phase I Clinical Trial Evaluating the Safety and Dosing of Relugolix with Novel Hormonal Therapy for the Treatment of Advanced Prostate Cancer. Target Oncol. 2023 05; 18(3):383-390. PMID: 37060432.
      Citations:    
    97. Mariados NF, Orio PF, Schiffman Z, Van TJ, Engelman A, Nurani R, Kurtzman SM, Lopez E, Chao M, Boike TP, Martinez AA, Gejerman G, Lederer J, Sylvester JE, Bell G, Rivera D, Shore N, Miller K, Sinayuk B, Steinberg ML, Low DA, Kishan AU, King MT. Hyaluronic Acid Spacer for Hypofractionated Prostate Radiation Therapy: A Randomized Clinical Trial. JAMA Oncol. 2023 04 01; 9(4):511-518. PMID: 36757690.
      Citations:    
    98. George DJ, Saad F, Cookson MS, Saltzstein DR, Tutrone R, Bossi A, Brown B, Selby B, Lu S, Buckley D, Tombal B, Shore ND. Impact of Concomitant Prostate Cancer Medications on Efficacy and Safety of Relugolix Versus Leuprolide in Men With Advanced Prostate Cancer. Clin Genitourin Cancer. 2023 06; 21(3):383-392.e2. PMID: 37062659.
      Citations:    
    99. Gillessen S, Bossi A, Davis ID, de Bono J, Fizazi K, James ND, Mottet N, Shore N, Small E, Smith M, Sweeney CJ, Tombal B, Antonarakis ES, Aparicio AM, Armstrong AJ, Attard G, Beer TM, Beltran H, Bjartell A, Blanchard P, Briganti A, Bristow RG, Bulbul M, Caffo O, Castellano D, Castro E, Cheng HH, Chi KN, Chowdhury S, Clarke CS, Clarke N, Daugaard G, De Santis M, Duran I, Eeles R, Efstathiou E, Efstathiou J, Ekeke ON, Evans CP, Fanti S, Feng FY, Fonteyne V, Fossati N, Frydenberg M, George D, Gleave M, Gravis G, Halabi S, Heinrich D, Herrmann K, Higano C, Hofman MS, Horvath LG, Hussain M, Jereczek-Fossa BA, Jones R, Kanesvaran R, Kellokumpu-Lehtinen PL, Khauli RB, Klotz L, Kramer G, Leibowitz R, Logothetis C, Mahal B, Maluf F, Mateo J, Matheson D, Mehra N, Merseburger A, Morgans AK, Morris MJ, Mrabti H, Mukherji D, Murphy DG, Murthy V, Nguyen PL, Oh WK, Ost P, O'Sullivan JM, Padhani AR, Pezaro CJ, Poon DMC, Pritchard CC, Rabah DM, Rathkopf D, Reiter RE, Rubin MA, Ryan CJ, Saad F, Sade JP, Sartor O, Scher HI, Sharifi N, Skoneczna I, Soule H, Spratt DE, Srinivas S, Sternberg CN, Steuber T, Suzuki H, Sydes MR, Taplin ME, Tilki D, T?rkeri L, Turco F, Uemura H, Uemura H, ?r?n Y, Vale CL, van Oort I, Vapiwala N, Walz J, Yamoah K, Ye D, Yu EY, Zapatero A, Zilli T, Omlin A. Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022. Eur J Cancer. 2023 05; 185:178-215. PMID: 37003085.
      Citations:    
    100. Shore N, Garcia-Horton V, Terasawa E, Ayyagari R, Grossman JP, Waldeck AR. Safety differences across androgen receptor inhibitors in nonmetastatic castration-resistant prostate cancer. Future Oncol. 2023 Feb; 19(5):385-395. PMID: 36794575.
      Citations:    
    101. Hussain M, Tombal B, Saad F, Fizazi K, Sternberg CN, Crawford ED, Shore N, Kopyltsov E, Kalebasty AR, B?gemann M, Ye D, Cruz F, Suzuki H, Kapur S, Srinivasan S, Verholen F, Kuss I, Joensuu H, Smith MR. Darolutamide Plus Androgen-Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer by Disease Volume and Risk Subgroups in the Phase III ARASENS Trial. J Clin Oncol. 2023 07 10; 41(20):3595-3607. PMID: 36795843.
      Citations:    
    102. Calais J, Eulau SM, Gardner L, Hauke RJ, Kendi AT, Shore ND, Zhao S. Incorporating radioligand therapy in clinical practice in the United States for patients with prostate cancer. Cancer Treat Rev. 2023 Apr; 115:102524. PMID: 36933329.
      Citations:    
    103. Hussain M, Sternberg CN, Efstathiou E, Fizazi K, Shen Q, Lin X, Sugg J, Steinberg J, Noerby B, De Giorgi U, Shore ND, Saad F. Nadir Prostate-specific Antigen as an Independent Predictor of Survival Outcomes: A Post Hoc Analysis of the PROSPER Randomized Clinical Trial. J Urol. 2023 03; 209(3):532-539. PMID: 36756959.
      Citations:    
    104. Shore ND, Cruz F, Nordquist L, Belkoff L, Aronson WJ, Tolia B, Cinman A, Sharifi R, Ortiz J, Parkin J, Srinivasan S, Sarapohja T, Smith MR. Efficacy and safety of darolutamide in Black/African-American patients from the phase III ARAMIS study. Future Oncol. 2022 Dec; 18(40):4473-4482. PMID: 36753353.
      Citations:    
    105. Broderick A, Labriola MK, Shore N, Armstrong AJ. Foreign accent syndrome as a heralding manifestation of transformation to small cell neuroendocrine prostate cancer. BMJ Case Rep. 2023 Jan 30; 16(1). PMID: 36717160.
      Citations:    
    106. Shore ND, Cooperberg MR, Tomlins SA. Antiandrogen Treatment vs Active Surveillance for Patients With Prostate Cancer-Reply. JAMA Oncol. 2023 01 01; 9(1):150-151. PMID: 36385364.
      Citations:    
    107. Shore ND, Gavaghan MB. Clinical and economic impact of blue light cystoscopy in the management of NMIBC at US ambulatory surgical centers: what is the site-of-service disparity? Urol Oncol. 2023 04; 41(4):207.e9-207.e16. PMID: 36564259.
      Citations:    
    108. O'Sullivan JM, McKay RR, Rahbar K, Fizazi K, George DJ, Tombal B, Schmall A, Sandstr?m P, Verholen F, Shore N. Real-world effectiveness, long-term safety and treatment pathway integration of radium-223 therapy in patients with metastatic castration-resistant prostate cancer. Front Med (Lausanne). 2022; 9. PMID: 36619649.
      Citations:    
    109. B?gemann M, Shore ND, Smith MR, Tammela TLJ, Ulys A, Vjaters E, Polyakov S, Jievaltas M, Luz M, Alekseev B, Lebret T, Schostak M, Verholen F, Le Berre MA, Srinivasan S, Ortiz J, Mohamed AF, Sarapohja T, Fizazi K. Erratum to "Efficacy and Safety of Darolutamide in Patients with Nonmetastatic Castration-resistant Prostate Cancer Stratified by Prostate-specific Antigen Doubling Time: Planned Subgroup Analysis of the Phase 3 ARAMIS Trial" [Eur Urol 2022]. Eur Urol. 2023 Feb; 83(2):e60. PMID: 36526492.
      Citations:    
    110. Gillessen S, Bossi A, Davis ID, de Bono J, Fizazi K, James ND, Mottet N, Shore N, Small E, Smith M, Sweeney C, Tombal B, Antonarakis ES, Aparicio AM, Armstrong AJ, Attard G, Beer TM, Beltran H, Bjartell A, Blanchard P, Briganti A, Bristow RG, Bulbul M, Caffo O, Castellano D, Castro E, Cheng HH, Chi KN, Chowdhury S, Clarke CS, Clarke N, Daugaard G, De Santis M, Duran I, Eeles R, Efstathiou E, Efstathiou J, Ngozi Ekeke O, Evans CP, Fanti S, Feng FY, Fonteyne V, Fossati N, Frydenberg M, George D, Gleave M, Gravis G, Halabi S, Heinrich D, Herrmann K, Higano C, Hofman MS, Horvath LG, Hussain M, Jereczek-Fossa BA, Jones R, Kanesvaran R, Kellokumpu-Lehtinen PL, Khauli RB, Klotz L, Kramer G, Leibowitz R, Logothetis CJ, Mahal BA, Maluf F, Mateo J, Matheson D, Mehra N, Merseburger A, Morgans AK, Morris MJ, Mrabti H, Mukherji D, Murphy DG, Murthy V, Nguyen PL, Oh WK, Ost P, O'Sullivan JM, Padhani AR, Pezaro C, Poon DMC, Pritchard CC, Rabah DM, Rathkopf D, Reiter RE, Rubin MA, Ryan CJ, Saad F, Pablo Sade J, Sartor OA, Scher HI, Sharifi N, Skoneczna I, Soule H, Spratt DE, Srinivas S, Sternberg CN, Steuber T, Suzuki H, Sydes MR, Taplin ME, Tilki D, T?rkeri L, Turco F, Uemura H, Uemura H, ?r?n Y, Vale CL, van Oort I, Vapiwala N, Walz J, Yamoah K, Ye D, Yu EY, Zapatero A, Zilli T, Omlin A. Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022. Eur Urol. 2023 03; 83(3):267-293. PMID: 36494221.
      Citations:    
    111. Brown G, Belkoff L, Hafron JM, Saltzstein DR, Potdar R, Bhaumik A, Phillips J, McGowan T, Shore ND. Coadministration of Apalutamide and Relugolix in Patients with Localized Prostate Cancer at High Risk for Metastases. Target Oncol. 2023 01; 18(1):95-103. PMID: 36472728.
      Citations:    
    112. Shore N, Mellado B, Shah S, Hauke R, Costin D, Adra N, Cullberg M, Teruel CF, Morris T. A Phase I Study of Capivasertib in Combination With Abiraterone Acetate in Patients With Metastatic Castration-Resistant Prostate Cancer. Clin Genitourin Cancer. 2023 04; 21(2):278-285. PMID: 36572571.
      Citations:    
    113. Shore ND, Morgans AK, El-Haddad G, Srinivas S, Abramowitz M. Addressing Challenges and Controversies in the Management of Prostate Cancer with Multidisciplinary Teams. Target Oncol. 2022 11; 17(6):709-725. PMID: 36399218.
      Citations:    
    114. Shore ND. Reply to Juan G?mez Rivas, Giorgio Gandaglia, and Francesco Montorsi's Letter to the Editor re: Neal D. Shore, Joseph Renzulli, Neil E. Fleshner, et al. Enzalutamide Monotherapy vs Active Surveillance in Patients with Low-risk or Intermediate-risk Localized Prostate Cancer: The ENACT Randomized Clinical Trial. JAMA Oncol 2022;8:1128-36. Eur Urol Open Sci. 2022 Dec; 46:145-146. PMID: 36420113.
      Citations:    
    115. De Giorgi U, Hussain M, Shore N, Fizazi K, Tombal B, Penson D, Saad F, Efstathiou E, Madziarska K, Steinberg J, Sugg J, Lin X, Shen Q, Sternberg CN. Which traits affect how long patients with advanced prostate cancer live when treated with enzalutamide? Future Oncol. 2022 11; 18(35):3867-3874. PMID: 36226865.
      Citations:    
    116. Shore ND, Stenzl A, Pieczonka C, Klaassen Z, Aronson WJ, Karsh L, Ryan CJ, Ortiz J, Srinivasan S, Mohamed AF, Verholen F. Impact of darolutamide on local symptoms: pre-planned and post hoc analyses of the ARAMIS trial. BJU Int. 2023 04; 131(4):452-460. PMID: 36087070.
      Citations:    
    117. Iczkowski KA, Molina M, Egevad L, Bostwick DG, van Leenders GJLH, La Rosa FG, van der Kwast T, Berney DM, Evans AJ, Wheeler TM, Leite KRM, Samaratunga H, Srigley J, Varma M, Tsuzuki T, Lucia MS, Crawford ED, Harris RG, Stricker P, Lawrentschuk N, Woo HH, Fleshner NE, Shore ND, Yaxley J, Bratt O, Wiklund P, Roberts M, Cheng L, Delahunt B. Low-grade prostate cancer should still be labelled cancer. BJU Int. 2022 12; 130(6):741-743. PMID: 36083240.
      Citations:    
    118. B?gemann M, Shore ND, Smith MR, Tammela TLJ, Ulys A, Vjaters E, Polyakov S, Jievaltas M, Luz M, Alekseev B, Lebret T, Schostak M, Verholen F, Le Berre MA, Srinivasan S, Ortiz J, Mohamed AF, Sarapohja T, Fizazi K. Efficacy and Safety of Darolutamide in Patients with Nonmetastatic Castration-resistant Prostate Cancer Stratified by Prostate-specific Antigen Doubling Time: Planned Subgroup Analysis of the Phase 3 ARAMIS Trial. Eur Urol. 2023 03; 83(3):212-221. PMID: 36089529.
      Citations:    
    119. Esplin ED, Nielsen SM, Bristow SL, Garber JE, Hampel H, Rana HQ, Samadder NJ, Shore ND, Nussbaum RL. Universal Germline Genetic Testing for Hereditary Cancer Syndromes in Patients With Solid Tumor Cancer. JCO Precis Oncol. 2022 09; 6:e2100516. PMID: 36108258.
      Citations:    
    120. Shore N, Jiang S, Garcia-Horton V, Terasawa E, Steffen D, Chin A, Ayyagari R, Partridge J, Waldeck AR. The Hospitalization-Related Costs of Adverse Events for Novel Androgen Receptor Inhibitors in Non-Metastatic Castration-Resistant Prostate Cancer: An Indirect Comparison. Adv Ther. 2022 11; 39(11):5025-5042. PMID: 36028656.
      Citations:    
    121. Beer TM, Shore N, Morgans A, Winters-Stone K, Wefel JS, George DJ. Functional impact of androgen-targeted therapy on patients with castration-resistant prostate cancer. BJUI Compass. 2022 Nov; 3(6):424-433. PMID: 36267196.
      Citations:    
    122. Morris MJ, Mota JM, Lacuna K, Hilden P, Gleave M, Carducci MA, Saad F, Cohn ED, Filipenko J, Heller G, Shore N, Armstrong AJ, Scher HI. Erratum to "Phase 3 Randomized Controlled Trial of Androgen Deprivation Therapy with or Without Docetaxel in High-risk Biochemically Recurrent Prostate Cancer After Surgery (TAX3503)" [Eur Urol Oncol 2021;4:543-52]. Eur Urol Oncol. 2022 Oct; 5(5):603. PMID: 35985981.
      Citations:    
    123. Agarwal N, Azad A, Shore ND, Carles J, Fay AP, Dunshee C, Karsh LI, Paccagnella ML, Santo ND, Elmeliegy M, Lin X, Czibere A, Fizazi K. Plain language summary of the design of the TALAPRO-2 study comparing talazoparib and enzalutamide versus enzalutamide and placebo in men with metastatic castration-resistant prostate cancer. Future Oncol. 2022 Sep; 18(27):2979-2986. PMID: 35950899.
      Citations:    
    124. Shore ND, Renzulli J, Fleshner NE, Hollowell CMP, Vourganti S, Silberstein J, Siddiqui R, Hairston J, Elsouda D, Russell D, Cooperberg MR, Tomlins SA. Enzalutamide Monotherapy vs Active Surveillance in Patients With Low-risk or Intermediate-risk Localized Prostate Cancer: The ENACT Randomized Clinical Trial. JAMA Oncol. 2022 08 01; 8(8):1128-1136. PMID: 35708696.
      Citations:    
    125. Stenzl A, Szmulewitz RZ, Petrylak D, Holzbeierlein J, Villers A, Azad A, Alcaraz A, Alekseev B, Iguchi T, Shore ND, Gomez-Veiga F, Ivanescu C, Rosbrook B, Ramaswamy K, Ganguli A, Haas GP, Armstrong AJ. The impact of enzalutamide on quality of life in men with metastatic hormone-sensitive prostate cancer based on prior therapy, risk, and symptom subgroups. Prostate. 2022 09; 82(13):1237-1247. PMID: 35675470.
      Citations:    
    126. Kamat AM, Lobo N, Lerner SP, Li R, Matulay JT, Palou J, Witjes JA, Roupr?t M, Smith AB, Chang SS, Shore ND, Steinberg GD, Dinney CP, Svatek RS, Lamm DL. Reduced Dose Intravesical Bacillus Calmette-Gu?rin: Why It Might Not Matter. Bladder Cancer. 2022; 8(2):113-117. PMID: 38993360.
      Citations:    
    127. Clarke NW, Armstrong AJ, Thiery-Vuillemin A, Oya M, Shore N, Loredo E, Procopio G, de Menezes J, Girotto G, Arslan C, Mehra N, Parnis F, Brown E, Schl?rmann F, Joung JY, Sugimoto M, Virizuela JA, Emmenegger U, Navratil J, Buchschacher GL, Poehlein C, Harrington EA, Desai C, Kang J, Saad F. Abiraterone and Olaparib for Metastatic Castration-Resistant Prostate Cancer. NEJM Evid. 2022 Sep; 1(9):EVIDoa2200043. PMID: 38319800.
      Citations:    
    128. Sweeney CJ, Percent IJ, Babu S, Cultrera JL, Mehlhaff BA, Goodman OB, Morris DS, Schnadig ID, Albany C, Shore ND, Sieber PR, Guba SC, Zhang W, Wacheck V, Donoho GP, Szpurka AM, Callies S, Lin BK, Bendell JC. Phase Ib/II Study of Enzalutamide with Samotolisib (LY3023414) or Placebo in Patients with Metastatic Castration-Resistant Prostate Cancer. Clin Cancer Res. 2022 06 01; 28(11):2237-2247. PMID: 35363301.
      Citations:    
    129. Shore ND, Sutton J. Plain language summary of the HERO study comparing relugolix with leuprolide for men with advanced prostate cancer. Future Oncol. 2022 Jul; 18(21):2575-2584. PMID: 35587650.
      Citations:    
    130. Roubaud G, ?zg?roglu M, Penel N, Matsubara N, Mehra N, Kolinsky MP, Procopio G, Feyerabend S, Joung JY, Gravis G, Nishimura K, Gedye C, Padua C, Shore N, Thiery-Vuillemin A, Saad F, van Alphen R, Carducci MA, Desai C, Brickel N, Poehlein C, Del Rosario P, Fizazi K. Olaparib tolerability and common adverse-event management in patients with metastatic castration-resistant prostate cancer: Further analyses from the PROfound study. Eur J Cancer. 2022 07; 170:73-84. PMID: 35598359.
      Citations:    
    131. Kates M, Mansour AM, Lamm DL, Shore N, Maulhardt H, Wendt A, Verco J, Marin A, Dewnani K, Verco S, diZerega GS. Phase 1/2 Trial Results of a Large Surface Area Microparticle Docetaxel for the Treatment of High-Risk Nonmuscle-Invasive Bladder Cancer. J Urol. 2022 10; 208(4):821-829. PMID: 35574612.
      Citations:    
    132. Jazayeri SB, Srivastava A, Shore N. Review of second-generation androgen receptor inhibitor therapies and their role in prostate cancer management. Curr Opin Urol. 2022 05 01; 32(3):283-291. PMID: 35552309.
      Citations:    
    133. Gillessen S, Armstrong A, Attard G, Beer TM, Beltran H, Bjartell A, Bossi A, Briganti A, Bristow RG, Bulbul M, Caffo O, Chi KN, Clarke CS, Clarke N, Davis ID, de Bono JS, Duran I, Eeles R, Efstathiou E, Efstathiou J, Ekeke ON, Evans CP, Fanti S, Feng FY, Fizazi K, Frydenberg M, George D, Gleave M, Halabi S, Heinrich D, Higano C, Hofman MS, Hussain M, James N, Jones R, Kanesvaran R, Khauli RB, Klotz L, Leibowitz R, Logothetis C, Maluf F, Millman R, Morgans AK, Morris MJ, Mottet N, Mrabti H, Murphy DG, Murthy V, Oh WK, Ost P, O'Sullivan JM, Padhani AR, Parker C, Poon DMC, Pritchard CC, Rabah DM, Rathkopf D, Reiter RE, Rubin M, Ryan CJ, Saad F, Sade JP, Sartor O, Scher HI, Shore N, Skoneczna I, Small E, Smith M, Soule H, Spratt DE, Sternberg CN, Suzuki H, Sweeney C, Sydes MR, Taplin ME, Tilki D, Tombal B, T?rkeri L, Uemura H, Uemura H, van Oort I, Yamoah K, Ye D, Zapatero A, Omlin A. Management of Patients with Advanced Prostate Cancer: Report from the Advanced Prostate Cancer Consensus Conference 2021. Eur Urol. 2022 07; 82(1):115-141. PMID: 35450732.
      Citations:    
    134. Turco F, Armstrong A, Attard G, Beer TM, Beltran H, Bjartell A, Bossi A, Briganti A, Bristow RG, Bulbul M, Caffo O, Chi KN, Clarke C, Clarke N, Davis ID, de Bono J, Duran I, Eeles R, Efstathiou E, Efstathiou J, Evans CP, Fanti S, Feng FY, Fizazi K, Frydenberg M, George D, Gleave M, Halabi S, Heinrich D, Higano C, Hofman MS, Hussain M, James N, Jones R, Kanesvaran R, Khauli RB, Klotz L, Leibowitz R, Logothetis C, Maluf F, Millman R, Morgans AK, Morris MJ, Mottet N, Mrabti H, Murphy DG, Murthy V, Oh WK, Ekeke ON, Ost P, O'Sullivan JM, Padhani AR, Parker C, Poon DMC, Pritchard CC, Rabah DM, Rathkopf D, Reiter RE, Rubin M, Ryan CJ, Saad F, Sade JP, Sartor O, Scher HI, Shore N, Skoneczna I, Small E, Smith M, Soule H, Spratt D, Sternberg CN, Suzuki H, Sweeney C, Sydes M, Taplin ME, Tilki D, Tombal B, T?rkeri L, Uemura H, Uemura H, van Oort I, Yamoah K, Ye D, Zapatero A, Gillessen S, Omlin A. Corrigendum to "What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021" [Eur Urol 82(1):6-11]. Eur Urol. 2022 Jul; 82(1):e18-e19. PMID: 35440417.
      Citations:    
    135. Hussain M, Corcoran C, Sibilla C, Fizazi K, Saad F, Shore N, Sandhu S, Mateo J, Olmos D, Mehra N, Kolinsky MP, Roubaud G, ?zg?roglu M, Matsubara N, Gedye C, Choi YD, Padua C, Kohlmann A, Huisden R, Elvin JA, Kang J, Adelman CA, Allen A, Poehlein C, de Bono J. Tumor Genomic Testing for >4,000 Men with Metastatic Castration-resistant Prostate Cancer in the Phase III Trial PROfound (Olaparib). Clin Cancer Res. 2022 04 14; 28(8):1518-1530. PMID: 35091440.
      Citations:    
    136. Armstrong AJ, Azad AA, Iguchi T, Szmulewitz RZ, Petrylak DP, Holzbeierlein J, Villers A, Alcaraz A, Alekseev B, Shore ND, Gomez-Veiga F, Rosbrook B, Zohren F, Yamada S, Haas GP, Stenzl A. Improved Survival With Enzalutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer. J Clin Oncol. 2022 05 20; 40(15):1616-1622. PMID: 35420921.
      Citations:    
    137. Lowentritt B, Brown G, Pilon D, Ellis L, Germain G, Rossi C, Lefebvre P, Kernen K, Sieber P, Shore N. Real-World Prostate-Specific Antigen Response and Treatment Adherence of Apalutamide in Patients With Non-Metastatic Castration-Resistant Prostate Cancer. Urology. 2022 08; 166:182-188. PMID: 35318045.
      Citations:    
    138. Shore ND, Lenz L, Cogan ES, Iliev D, Spencer L, Flake DD, Meek S, Davis T, Copeland K, Finch R, Schiff W, Korman H, Rao M, Belkoff L, Jalkut M, Mariados N, D'Anna R, Mehlhaff B, Slavin TP, Cohen TD. Hereditary cancer risk assessment and genetic testing in the community urology practice setting. Prostate. 2022 05; 82(7):850-857. PMID: 35239202.
      Citations:    
    139. George DJ, Agarwal N, Sartor O, Sternberg CN, Tombal B, Saad F, Miller K, Constantinovici N, Guo H, Reeves J, Jiao X, Sandstr?m P, Verholen F, Higano CS, Shore N. Real-world patient characteristics associated with survival of 2 years or more after radium-223 treatment for metastatic castration-resistant prostate cancer (EPIX study). Prostate Cancer Prostatic Dis. 2022 02; 25(2):306-313. PMID: 35190653.
      Citations:    
    140. Turco F, Armstrong A, Attard G, Beer TM, Beltran H, Bjartell A, Bossi A, Briganti A, Bristow RG, Bulbul M, Caffo O, Chi KN, Clarke C, Clarke N, Davis ID, de Bono J, Duran I, Eeles R, Efstathiou E, Efstathiou J, Evans CP, Fanti S, Feng FY, Fizazi K, Frydenberg M, George D, Gleave M, Halabi S, Heinrich D, Higano C, Hofman MS, Hussain M, James N, Jones R, Kanesvaran R, Khauli RB, Klotz L, Leibowitz R, Logothetis C, Maluf F, Millman R, Morgans AK, Morris MJ, Mottet N, Mrabti H, Murphy DG, Murthy V, Oh WK, Ekeke Onyeanunam N, Ost P, O'Sullivan JM, Padhani AR, Parker C, Poon DMC, Pritchard CC, Rabah DM, Rathkopf D, Reiter RE, Rubin M, Ryan CJ, Saad F, Pablo Sade J, Sartor O, Scher HI, Shore N, Skoneczna I, Small E, Smith M, Soule H, Spratt D, Sternberg CN, Suzuki H, Sweeney C, Sydes M, Taplin ME, Tilki D, Tombal B, T?rkeri L, Uemura H, Uemura H, van Oort I, Yamoah K, Ye D, Zapatero A, Gillessen S, Omlin A. What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021. Eur Urol. 2022 07; 82(1):6-11. PMID: 35393158.
      Citations:    
    141. Thiery-Vuillemin A, de Bono J, Hussain M, Roubaud G, Procopio G, Shore N, Fizazi K, Dos Anjos G, Gravis G, Joung JY, Matsubara N, Castellano D, Degboe A, Gresty C, Kang J, Allen A, Poehlein C, Saad F. Pain and health-related quality of life with olaparib versus physician's choice of next-generation hormonal drug in patients with metastatic castration-resistant prostate cancer with homologous recombination repair gene alterations (PROfound): an open-label, randomised, phase 3 trial. Lancet Oncol. 2022 03; 23(3):393-405. PMID: 35157830.
      Citations:    
    142. Agarwal N, Azad A, Shore ND, Carles J, Fay AP, Dunshee C, Karsh LI, Paccagnella ML, Santo ND, Elmeliegy M, Lin X, Czibere A, Fizazi K. Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: TALAPRO-2 phase III study design. Future Oncol. 2022 Feb; 18(4):425-436. PMID: 35080190.
      Citations:    
    143. Mitra AP, Narayan VM, Mokkapati S, Miest T, Boorjian SA, Alemozaffar M, Konety BR, Shore ND, Gomella LG, Kamat AM, Bivalacqua TJ, Montgomery JS, Lerner SP, Busby JE, Poch M, Crispen PL, Steinberg GD, Schuckman AK, Downs TM, Svatek RS, Mashni J, Lane BR, Guzzo TJ, Bratslavsky G, Karsh LI, Woods ME, Brown GA, Canter D, Luchey A, Lotan Y, Krupski T, Inman BA, Williams MB, Cookson MS, Keegan KA, Andriole GL, Sankin AI, Boyd A, O'Donnell MA, Philipson R, Yl?-Herttuala S, Sawutz D, Parker NR, McConkey DJ, Dinney CPN. Antiadenovirus Antibodies Predict Response Durability to Nadofaragene Firadenovec Therapy in BCG-unresponsive Non-muscle-invasive Bladder Cancer: Secondary Analysis of a Phase 3 Clinical Trial. Eur Urol. 2022 03; 81(3):223-228. PMID: 34933753.
      Citations:    
    144. Vogl UM, Beer TM, Davis ID, Shore ND, Sweeney CJ, Ost P, Attard G, Bossi A, de Bono J, Drake CG, Efstathiou E, Fanti S, Fizazi K, Halabi S, James N, Mottet N, Padhani AR, Roach M, Rubin M, Sartor O, Small E, Smith MR, Soule H, Sydes MR, Tombal B, Omlin A, Gillessen S. Lack of consensus identifies important areas for future clinical research: Advanced Prostate Cancer Consensus Conference (APCCC) 2019 findings. Eur J Cancer. 2022 01; 160:24-60. PMID: 34844839.
      Citations:    
    145. De Giorgi U, Hussain M, Shore N, Fizazi K, Tombal B, Penson D, Saad F, Efstathiou E, Madziarska K, Steinberg J, Sugg J, Lin X, Shen Q, Sternberg CN. Consistent survival benefit of enzalutamide plus androgen deprivation therapy in men with nonmetastatic castration-resistant prostate cancer: PROSPER subgroup analysis by age and region. Eur J Cancer. 2021 12; 159:237-246. PMID: 34784577.
      Citations:    
    146. Klotz L, Andriole G, Cash H, Cooperberg M, Crawford ED, Emberton M, Gomez-Sancha F, Klein E, Lughezzani G, Marks L, Montorsi F, Salomon G, Sanchez-Salas R, Shore N, Taneja S. Optimization of prostate biopsy - Micro-Ultrasound versus MRI (OPTIMUM): A 3-arm randomized controlled trial evaluating the role of 29?MHz micro-ultrasound in guiding prostate biopsy in men with clinical suspicion of prostate cancer. Contemp Clin Trials. 2022 01; 112:106618. PMID: 34728381.
      Citations:    
    147. Sartor O, George D, Tombal B, Agarwal N, Higano CS, Sternberg CN, Miller K, Jiao X, Guo H, Sandstr?m P, Bruno A, Verholen F, Saad F, Shore N. Real-world outcomes of second novel hormonal therapy or radium-223 following first novel hormonal therapy for mCRPC. Future Oncol. 2022 Jan; 18(1):35-45. PMID: 34636627.
      Citations:    
    148. Tward J, Lenz L, Flake DD, Rajamani S, Yonover P, Olsson C, Kapoor DA, Mantz C, Liauw SL, Antic T, Fabrizio M, Salzstein D, Shore N, Albertson D, Henderson J, Lee SP, Gay HA, Michalski J, Hung A, Raben D, Garraway I, Lewis MS, Nguyen PL, Marshall DT, Brawer MK, Stone S, Cohen T. The Clinical Cell-Cycle Risk (CCR) Score Is Associated With Metastasis After Radiation Therapy and Provides Guidance on When to Forgo Combined Androgen Deprivation Therapy With Dose-Escalated Radiation. Int J Radiat Oncol Biol Phys. 2022 05 01; 113(1):66-76. PMID: 34610388.
      Citations:    
    149. Spratt DE, Shore N, Sartor O, Rathkopf D, Olivier K. Correction: Treating the patient and not just the cancer: therapeutic burden in prostate cancer. Prostate Cancer Prostatic Dis. 2021 Sep; 24(3):927. PMID: 33785848.
      Citations:    
    150. Chevli KK, Shore ND, Trainer A, Smith AB, Saltzstein D, Ehrlich Y, Raman JD, Friedman B, D'Anna R, Morris D, Hu B, Tyson M, Sankin A, Kates M, Linehan J, Scherr D, Kester S, Verni M, Chamie K, Karsh L, Cinman A, Meads A, Lahiri S, Malinowski M, Gabai N, Raju S, Schoenberg M, Seltzer E, Huang WC. Primary Chemoablation of Low-Grade Intermediate-Risk Nonmuscle-Invasive Bladder Cancer Using UGN-102, a Mitomycin-Containing Reverse Thermal Gel (Optima II): A Phase 2b, Open-Label, Single-Arm Trial. J Urol. 2022 01; 207(1):61-69. PMID: 34433303.
      Citations:    
    151. Azad AA, Armstrong AJ, Alcaraz A, Szmulewitz RZ, Petrylak DP, Holzbeierlein J, Villers A, Alekseev B, Iguchi T, Shore ND, Gomez-Veiga F, Rosbrook B, Lee HJ, Haas GP, Stenzl A. Efficacy of enzalutamide in subgroups of men with metastatic hormone-sensitive prostate cancer based on prior therapy, disease volume, and risk. Prostate Cancer Prostatic Dis. 2022 02; 25(2):274-282. PMID: 34420037.
      Citations:    
    152. Freedland SJ, De Giorgi U, Gleave M, Rosbrook B, Shen Q, Sugg J, Haas GP, Shore ND. A phase 3 randomised study of enzalutamide plus leuprolide and enzalutamide monotherapy in high-risk non-metastatic hormone-sensitive prostate cancer with rising PSA after local therapy: EMBARK study design. BMJ Open. 2021 08 12; 11(8):e046588. PMID: 34385241.
      Citations:    
    153. Shore ND, Lalibert? F, Ionescu-Ittu R, Yang L, Mahendran M, Lejeune D, Yu LH, Burgents J, Duh MS, Ghate SR. Real-World Treatment Patterns and Overall Survival of Patients with Metastatic Castration-Resistant Prostate Cancer in the US Prior to PARP Inhibitors. Adv Ther. 2021 08; 38(8):4520-4540. PMID: 34282527.
      Citations:    
    154. Smith MR, Shore N, Tammela TL, Ulys A, Vjaters E, Polyakov S, Jievaltas M, Luz M, Alekseev B, Kuss I, Le Berre MA, Mohamed AF, Odom D, Bartsch J, Snapir A, Sarapohja T, Fizazi K. Darolutamide and health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: An analysis of the phase III ARAMIS trial. Eur J Cancer. 2021 09; 154:138-146. PMID: 34273811.
      Citations:    
    155. Shore ND, Ionescu-Ittu R, Lalibert? F, Yang L, Lejeune D, Yu L, Duh MS, Mahendran M, Kim J, Ghate SR. Beyond Frontline Therapy with Abiraterone and Enzalutamide in Metastatic Castration-Resistant Prostate Cancer: A Real-World US Study. Clin Genitourin Cancer. 2021 12; 19(6):480-490. PMID: 34373223.
      Citations:    
    156. Galsky MD, Balar AV, Black PC, Campbell MT, Dykstra GS, Grivas P, Gupta S, Hoimes CJ, Lopez LP, Meeks JJ, Plimack ER, Rosenberg JE, Shore N, Steinberg GD, Kamat AM. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of urothelial cancer. J Immunother Cancer. 2021 07; 9(7). PMID: 34266883.
      Citations:    
    157. Shore ND, Palou Redorta J, Robert G, Hutson TE, Cesari R, Hariharan S, Rodr?guez Faba ?, Briganti A, Steinberg GD. Non-muscle-invasive bladder cancer: An overview of potential new treatment options. Urol Oncol. 2021 10; 39(10):642-663. PMID: 34167873.
      Citations:    
    158. Srivastava A, Shore ND. Combined advanced prostate cancer treatments: are they additive? Nat Rev Urol. 2021 06; 18(6):325-326. PMID: 33758370.
      Citations:    
    159. Galsky MD, Hoimes CJ, Necchi A, Shore N, Witjes JA, Steinberg G, Bedke J, Nishiyama H, Fang X, Kataria R, Sbar E, Jia X, Siefker-Radtke A. Perioperative pembrolizumab therapy in muscle-invasive bladder cancer: Phase III KEYNOTE-866 and KEYNOTE-905/EV-303. Future Oncol. 2021 Aug; 17(24):3137-3150. PMID: 34008425.
      Citations:    
    160. Morris MJ, Mota JM, Lacuna K, Hilden P, Gleave M, Carducci MA, Saad F, Cohn ED, Filipenko J, Heller G, Shore N, Armstrong AJ, Scher HI. Phase 3 Randomized Controlled Trial of Androgen Deprivation Therapy with or Without Docetaxel in High-risk Biochemically Recurrent Prostate Cancer After Surgery (TAX3503). Eur Urol Oncol. 2021 08; 4(4):543-552. PMID: 34020931.
      Citations:    
    161. Chughtai B, Rojanasarot S, Neeser K, Gultyaev D, Amorosi SL, Shore ND. Cost-Effectiveness and Budget Impact of Emerging Minimally Invasive Surgical Treatments for Benign Prostatic Hyperplasia. J Health Econ Outcomes Res. 2021 May 06; 8(1):42-50. PMID: 33987450.
      Citations:    
    162. Coelingh Bennink HJT, van Moorselaar JA, Crawford ED, Roos EPM, Somford DM, Roeleveld TA, de Haan TD, van Melick HHE, Reisman Y, Zimmerman Y, van Osta G, Krijgh J, Shore ND, Saad F, Schally AV, Debruyne FMJ. Estetrol Cotreatment of Androgen Deprivation Therapy in Infiltrating or Metastatic, Castration-sensitive Prostate Cancer: A Randomized, Double-blind, Phase II Trial (PCombi). Eur Urol Open Sci. 2021 Jun; 28:52-61. PMID: 34337526.
      Citations:    
    163. Shore N, Ionescu-Ittu R, Yang L, Lalibert? F, Mahendran M, Lejeune D, Yu L, Burgents J, Duh MS, Ghate SR. Real-world genetic testing patterns in metastatic castration-resistant prostate cancer. Future Oncol. 2021 Aug; 17(22):2907-2921. PMID: 33906368.
      Citations:    
    164. Halabi S, Jiang S, Terasawa E, Garcia-Horton V, Ayyagari R, Waldeck AR, Shore N. Indirect Comparison of Darolutamide versus Apalutamide and Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer. J Urol. 2021 Aug; 206(2):298-307. PMID: 33818140.
      Citations:    
    165. Ledet EM, Burgess EF, Sokolova AO, Jaeger EB, Hatton W, Moses M, Miller P, Cotogno P, Layton J, Barata P, Lewis BE, Nakazawa M, Zhu J, Dellinger B, Elrefai S, Nafissi NN, Egan JB, Shore N, McKay RR, Bryce AH, Cheng HH, Antonarakis ES, Sartor O. Comparison of germline mutations in African American and Caucasian men with metastatic prostate cancer. Prostate. 2021 05; 81(7):433-439. PMID: 33792945.
      Citations:    
    166. Saad F, Shore ND. Relugolix: a novel androgen deprivation therapy for management of patients with advanced prostate cancer. Ther Adv Med Oncol. 2021; 13:1758835921998586. PMID: 34408793.
      Citations:    
    167. Saad F, Chi KN, Shore ND, Graff JN, Posadas EM, Lattouf JB, Espina BM, Zhu E, Yu A, Hazra A, De Meulder M, Mamidi RNVS, Bradic B, Francis P, Hayreh V, Rezazadeh Kalebasty A. Niraparib with androgen receptor-axis-targeted therapy in patients with metastatic castration-resistant prostate cancer: safety and pharmacokinetic results from a phase 1b study (BEDIVERE). Cancer Chemother Pharmacol. 2021 07; 88(1):25-37. PMID: 33754187.
      Citations:    
    168. Morgans AK, Renzulli J, Olivier K, Shore ND. Risk of Cognitive Effects in Comorbid Patients With Prostate Cancer Treated With Androgen Receptor Inhibitors. Clin Genitourin Cancer. 2021 10; 19(5):467.e1-467.e11. PMID: 33893042.
      Citations:    
    169. Rentz AM, Mansukhani SG, Liu J, Lloyd AJ, Heidenreich S, Matza LS, Dawson NA, Shore N, Freedland SJ. Patients' preferences for delaying metastatic castration-resistant prostate cancer: Combining health state and treatment valuation. Urol Oncol. 2021 06; 39(6):367.e7-367.e17. PMID: 33736976.
      Citations:    
    170. Armstrong AJ, Shore ND, Szmulewitz RZ, Petrylak DP, Holzbeierlein J, Villers A, Azad A, Alcaraz A, Alekseev B, Iguchi T, Gomez-Veiga F, Rosbrook B, Lee HJ, Haas GP, Stenzl A. Reply by Authors. J Urol. 2021 05; 205(5):1371. PMID: 33705222.
      Citations:    
    171. Spratt DE, Shore N, Sartor O, Rathkopf D, Olivier K. Treating the patient and not just the cancer: therapeutic burden in prostate cancer. Prostate Cancer Prostatic Dis. 2021 09; 24(3):647-661. PMID: 33603236.
      Citations:    
    172. Saad F, B?gemann M, Suzuki K, Shore N. Treatment of nonmetastatic castration-resistant prostate cancer: focus on second-generation androgen receptor inhibitors. Prostate Cancer Prostatic Dis. 2021 06; 24(2):323-334. PMID: 33558665.
      Citations:    
    173. Klotz L, Lughezzani G, Maffei D, S?nchez A, Pereira JG, Staerman F, Cash H, Luger F, Lopez L, Sanchez-Salas R, Abouassaly R, Shore ND, Eure G, Paciotti M, Astobieta A, Wiemer L, Hofbauer S, Heckmann R, Gusenleitner A, Kaar J, Mayr C, Loidl W, Rouffilange J, Gaston R, Cathelineau X, Klein E. Comparison of micro-ultrasound and multiparametric magnetic resonance imaging for prostate cancer: A multicenter, prospective analysis. Can Urol Assoc J. 2021 01; 15(1):E11-E16. PMID: 32701437.
      Citations:    
    174. Armstrong AJ, Shore ND, Szmulewitz RZ, Petrylak DP, Holzbeierlein J, Villers A, Azad A, Alcaraz A, Alekseev B, Iguchi T, Gomez-Veiga F, Rosbrook B, Lee HJ, Haas GP, Stenzl A. Efficacy of Enzalutamide plus Androgen Deprivation Therapy in Metastatic Hormone-Sensitive Prostate Cancer by Pattern of Metastatic Spread: ARCHES Post Hoc Analyses. J Urol. 2021 May; 205(5):1361-1371. PMID: 33356529.
      Citations:    
    175. Chughtai B, Elterman D, Shore N, Gittleman M, Motola J, Pike S, Hermann C, Terrens W, Kohan A, Gonzalez RR, Katz A, Schiff J, Goldfischer E, Grunberger I, Tu LM, Alshak MN, Kaminetzky J. The iTind Temporarily Implanted Nitinol Device for the Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia: A Multicenter, Randomized, Controlled Trial. Urology. 2021 07; 153:270-276. PMID: 33373708.
      Citations:    
    176. Shore N, Oliver L, Shui I, Gayle A, Wong OY, Kim J, Payne S, Amin S, Ghate S. Systematic Literature Review of the Epidemiology of Advanced Prostate Cancer and Associated Homologous Recombination Repair Gene Alterations. J Urol. 2021 04; 205(4):977-986. PMID: 33332152.
      Citations:    
    177. Boorjian SA, Alemozaffar M, Konety BR, Shore ND, Gomella LG, Kamat AM, Bivalacqua TJ, Montgomery JS, Lerner SP, Busby JE, Poch M, Crispen PL, Steinberg GD, Schuckman AK, Downs TM, Svatek RS, Mashni J, Lane BR, Guzzo TJ, Bratslavsky G, Karsh LI, Woods ME, Brown G, Canter D, Luchey A, Lotan Y, Krupski T, Inman BA, Williams MB, Cookson MS, Keegan KA, Andriole GL, Sankin AI, Boyd A, O'Donnell MA, Sawutz D, Philipson R, Coll R, Narayan VM, Treasure FP, Yla-Herttuala S, Parker NR, Dinney CPN. Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial. Lancet Oncol. 2021 01; 22(1):107-117. PMID: 33253641.
      Citations:    
    178. Uemura H, Matsushima H, Kobayashi K, Mizusawa H, Nishimatsu H, Fizazi K, Smith M, Shore N, Tammela T, Tabata KI, Matsubara N, Iinuma M, Uemura H, Oya M, Momma T, Kawakita M, Fukasawa S, Kobayashi T, Kuss I, Le Berre MA, Snapir A, Sarapohja T, Suzuki K. Efficacy and safety of darolutamide in Japanese patients with nonmetastatic castration-resistant prostate cancer: a sub-group analysis of the phase III ARAMIS trial. Int J Clin Oncol. 2021 Mar; 26(3):578-590. PMID: 33226524.
      Citations:    
    179. Crawford ED, Hafron JM, Tagawa ST, Twardowski PW, Harris RG, Moul JW, Keane TE, Concepcion RS, Higano CS, Gordan LN, Petrylak DP, Cross CK, Kader AK, Shore ND. Impact of Late Dosing on Testosterone Suppression with 2 Different Leuprolide Acetate Formulations: In Situ Gel and Microsphere. An Analysis of United States Clinical Data. J Urol. 2021 02; 205(2):554-560. PMID: 33090917.
      Citations:    
    180. Saad F, Sternberg CN, Efstathiou E, Fizazi K, Modelska K, Lin X, Sugg J, Steinberg J, Noerby B, Shore ND, Hussain M. Prostate-specific Antigen Progression in Enzalutamide-treated Men with Nonmetastatic Castration-resistant Prostate Cancer: Any Rise in Prostate-specific Antigen May Require Closer Monitoring. Eur Urol. 2020 12; 78(6):847-853. PMID: 33010985.
      Citations:    
    181. Hussain M, Mateo J, Fizazi K, Saad F, Shore N, Sandhu S, Chi KN, Sartor O, Agarwal N, Olmos D, Thiery-Vuillemin A, Twardowski P, Roubaud G, ?zg?roglu M, Kang J, Burgents J, Gresty C, Corcoran C, Adelman CA, de Bono J. Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer. N Engl J Med. 2020 12 10; 383(24):2345-2357. PMID: 32955174.
      Citations:    
    182. Morgans AK, Shore N, Cope D, McNatty A, Moslehi J, Gomella L, Sartor O. Androgen receptor inhibitor treatments: Cardiovascular adverse events and comorbidity considerations in patients with non-metastatic prostate cancer. Urol Oncol. 2021 01; 39(1):52-62. PMID: 32958445.
      Citations:    
    183. Fizazi K, Shore N, Tammela TL, Ulys A, Vjaters E, Polyakov S, Jievaltas M, Luz M, Alekseev B, Kuss I, Le Berre MA, Petrenciuc O, Snapir A, Sarapohja T, Smith MR. Nonmetastatic, Castration-Resistant Prostate Cancer and Survival with Darolutamide. N Engl J Med. 2020 09 10; 383(11):1040-1049. PMID: 32905676.
      Citations:    
    184. Shore ND, Morgans AK, Ryan CJ. Resetting the Bar of Castration Resistance - Understanding Androgen Dynamics in Therapy Resistance and Treatment Choice in Prostate Cancer. Clin Genitourin Cancer. 2021 06; 19(3):199-207. PMID: 33129718.
      Citations:    
    185. Shore ND, Dearnaley D, Tombal B. Reply to Brandon A. Mahal, Anthony V. D'Amico, and Paul L. Nguyen's Letter to the Editor re: Neal D. Shore, Fred Saad, Michael S. Cookson, et al. Oral Relugolix for Androgen Deprivation Therapy in Advanced Prostate Cancer. N Engl J Med 2020;382:2187-96. Eur Urol. 2020 11; 78(5):e196-e197. PMID: 32838997.
      Citations:    
    186. Shore ND, Drake CG, Lin DW, Ryan CJ, Stratton KL, Dunshee C, Karsh LI, Kaul S, Kernen K, Pieczonka C, Sieber P, Stewart C, Williams M, Concepcion RS. Optimizing the management of castration-resistant prostate cancer patients: A practical guide for clinicians. Prostate. 2020 10; 80(14):1159-1176. PMID: 32779781.
      Citations:    
    187. Zhang T, Harrison MR, O'Donnell PH, Alva AS, Hahn NM, Appleman LJ, Cetnar J, Burke JM, Fleming MT, Milowsky MI, Mortazavi A, Shore N, Sonpavde GP, Schmidt EV, Bitman B, Munugalavadla V, Izumi R, Patel P, Staats J, Chan C, Weinhold KJ, George DJ. A randomized phase 2 trial of pembrolizumab versus pembrolizumab and acalabrutinib in patients with platinum-resistant metastatic urothelial cancer. Cancer. 2020 10 15; 126(20):4485-4497. PMID: 32757302.
      Citations:    
    188. Sternberg CN, Fizazi K, Saad F, Shore ND, De Giorgi U, Penson DF, Ferreira U, Efstathiou E, Madziarska K, Kolinsky MP, Cubero DIG, Noerby B, Zohren F, Lin X, Modelska K, Sugg J, Steinberg J, Hussain M. Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer. N Engl J Med. 2020 06 04; 382(23):2197-2206. PMID: 32469184.
      Citations:    
    189. Shore ND, Saad F, Cookson MS, George DJ, Saltzstein DR, Tutrone R, Akaza H, Bossi A, van Veenhuyzen DF, Selby B, Fan X, Kang V, Walling J, Tombal B. Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer. N Engl J Med. 2020 06 04; 382(23):2187-2196. PMID: 32469183.
      Citations:    
    190. Shore N, Higano CS, George DJ, Sternberg CN, Saad F, Tombal B, Miller K, Kalinovsky J, Jiao X, Tangirala K, Sartor O. Concurrent or layered treatment with radium-223 and enzalutamide or abiraterone/prednisone: real-world clinical outcomes in patients with metastatic castration-resistant prostate cancer. Prostate Cancer Prostatic Dis. 2020 12; 23(4):680-688. PMID: 32404868.
      Citations:    
    191. Shore ND, Pieczonka CM, Henderson RJ, Bailen JL, Saltzstein DR, Concepcion RS, Beebe-Dimmer JL, Ruterbusch JJ, Le TH, Levin RA, Wissmueller S, Prah P, Borotkanics R, Paivanas TA, van Breda A, Campbell DH, Walsh BJ. A comparison of prostate health index, total PSA, %free PSA, and proPSA in a contemporary US population-The MiCheck-01 prospective trial. Urol Oncol. 2020 08; 38(8):683.e1-683.e10. PMID: 32360170.
      Citations:    
    192. de Bono J, Mateo J, Fizazi K, Saad F, Shore N, Sandhu S, Chi KN, Sartor O, Agarwal N, Olmos D, Thiery-Vuillemin A, Twardowski P, Mehra N, Goessl C, Kang J, Burgents J, Wu W, Kohlmann A, Adelman CA, Hussain M. Olaparib for Metastatic Castration-Resistant Prostate Cancer. N Engl J Med. 2020 05 28; 382(22):2091-2102. PMID: 32343890.
      Citations:    
    193. Shore ND, Schellhammer PF, Tutrone RF, Mariados NF, Harrelson SS. Open Label Phase II Study of Enzalutamide With Concurrent Administration of Radium 223 Dichloride in Patients With Castration-Resistant Prostate Cancer. Clin Genitourin Cancer. 2020 10; 18(5):416-422. PMID: 32475774.
      Citations:    
    194. Shore ND, Pieczonka CM, Henderson RJ, Bailen JL, Saltzstein DR, Concepcion RS, Beebe-Dimmer JL, Ruterbusch JJ, Levin RA, Wissmueller S, Le TH, Gillatt D, Chan DW, Campbell DH, Walsh BJ. Development and evaluation of the MiCheck test for aggressive prostate cancer. Urol Oncol. 2020 08; 38(8):683.e11-683.e18. PMID: 32305266.
      Citations:    
    195. Dearnaley DP, Saltzstein DR, Sylvester JE, Karsh L, Mehlhaff BA, Pieczonka C, Bailen JL, Shi H, Ye Z, Faessel HM, Lin H, Zhu Y, Saad F, MacLean DB, Shore ND. The Oral Gonadotropin-releasing Hormone Receptor Antagonist Relugolix as Neoadjuvant/Adjuvant Androgen Deprivation Therapy to External Beam Radiotherapy in Patients with Localised Intermediate-risk Prostate Cancer: A Randomised, Open-label, Parallel-group Phase 2 Trial. Eur Urol. 2020 08; 78(2):184-192. PMID: 32273183.
      Citations:    
    196. Kamat AM, Shore N, Hahn N, Alanee S, Nishiyama H, Shariat S, Nam K, Kapadia E, Frenkl T, Steinberg G. KEYNOTE-676: Phase III study of BCG and pembrolizumab for persistent/recurrent high-risk NMIBC. Future Oncol. 2020 Apr; 16(10):507-516. PMID: 32162533.
      Citations:    
    197. Higano CS, Armstrong AJ, Sartor O, Vogelzang NJ, Kantoff PW, McLeod DG, Pieczonka CM, Penson DF, Shore ND, Vacirca J, Concepcion RS, Tutrone RF, Nordquist LT, Quinn DI, Kassabian V, Scholz MC, Harmon M, Tyler RC, Chang NN, Tang H, Cooperberg MR. Reply to Potential underestimation of cerebrovascular events in the PROVENGE Registry for the Observation, Collection, and Evaluation of Experience Data. Cancer. 2020 06 15; 126(12):2935-2937. PMID: 32154908.
      Citations:    
    198. Shore ND, Antonarakis ES, Cookson MS, Crawford ED, Morgans AK, Albala DM, Hafron J, Harris RG, Saltzstein D, Brown GA, Henderson J, Lowentritt B, Spier JM, Concepcion R. Optimizing the role of androgen deprivation therapy in advanced prostate cancer: Challenges beyond the guidelines. Prostate. 2020 05; 80(6):527-544. PMID: 32130741.
      Citations:    
    199. Shore ND, Morrow MP, McMullan T, Kraynyak KA, Sylvester A, Bhatt K, Cheung J, Boyer JD, Liu L, Sacchetta B, Rosencranz S, Heath EI, Nordquist L, Cheng HH, Tagawa ST, Appleman LJ, Tutrone R, Garcia JA, Whang YE, Kelly WK, Weiner DB, Bagarazzi ML, Skolnik JM. CD8+ T Cells Impact Rising PSA in Biochemically Relapsed Cancer Patients Using Immunotherapy Targeting Tumor-Associated Antigens. Mol Ther. 2020 05 06; 28(5):1238-1250. PMID: 32208168.
      Citations:    
    200. Schulte B, Morgans AK, Shore ND, Pezaro C. Sorting Through the Maze of Treatment Options for Metastatic Castration-Sensitive Prostate Cancer. Am Soc Clin Oncol Educ Book. 2020 Mar; 40:1-10. PMID: 32182139.
      Citations:    
    201. Sartor O, Armstrong AJ, Ahaghotu C, McLeod DG, Cooperberg MR, Penson DF, Kantoff PW, Vogelzang NJ, Hussain A, Pieczonka CM, Shore ND, Quinn DI, Small EJ, Heath EI, Tutrone RF, Schellhammer PF, Harmon M, Chang NN, Sheikh NA, Brown B, Freedland SJ, Higano CS. Survival of African-American and Caucasian men after sipuleucel-T immunotherapy: outcomes from the PROCEED registry. Prostate Cancer Prostatic Dis. 2020 09; 23(3):517-526. PMID: 32111923.
      Citations:    
    202. Shore N, Kaplan SA, Tutrone R, Levin R, Bailen J, Hay A, Kalota S, Bidair M, Freedman S, Goldberg K, Snoy F, Epstein JI. Prospective evaluation of fexapotide triflutate injection treatment of Grade Group 1 prostate cancer: 4-year results. World J Urol. 2020 Dec; 38(12):3101-3111. PMID: 32088746.
      Citations:    
    203. Gillessen S, Attard G, Beer TM, Beltran H, Bjartell A, Bossi A, Briganti A, Bristow RG, Chi KN, Clarke N, Davis ID, de Bono J, Drake CG, Duran I, Eeles R, Efstathiou E, Evans CP, Fanti S, Feng FY, Fizazi K, Frydenberg M, Gleave M, Halabi S, Heidenreich A, Heinrich D, Higano CTS, Hofman MS, Hussain M, James N, Kanesvaran R, Kantoff P, Khauli RB, Leibowitz R, Logothetis C, Maluf F, Millman R, Morgans AK, Morris MJ, Mottet N, Mrabti H, Murphy DG, Murthy V, Oh WK, Ost P, O'Sullivan JM, Padhani AR, Parker C, Poon DMC, Pritchard CC, Reiter RE, Roach M, Rubin M, Ryan CJ, Saad F, Sade JP, Sartor O, Scher HI, Shore N, Small E, Smith M, Soule H, Sternberg CN, Steuber T, Suzuki H, Sweeney C, Sydes MR, Taplin ME, Tombal B, T?rkeri L, van Oort I, Zapatero A, Omlin A. Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019. Eur Urol. 2020 04; 77(4):508-547. PMID: 32001144.
      Citations:    
    204. Raman J, Shore ND. Management of Low-grade Upper Tract Urothelial Carcinoma: An Unmet Need. Rev Urol. 2020; 22(1):1-8. PMID: 32523465.
      Citations:    
    205. Shore ND. Current and Future Management of Locally Advanced and Metastatic Prostate Cancer. Rev Urol. 2020; 22(3):110-123. PMID: 33239970.
      Citations:    
    206. Petrylak DP, Vogelzang NJ, Chatta K, Fleming MT, Smith DC, Appleman LJ, Hussain A, Modiano M, Singh P, Tagawa ST, Gore I, McClay EF, Mega AE, Sartor AO, Somer B, Wadlow R, Shore ND, Olson WC, Stambler N, DiPippo VA, Israel RJ. PSMA ADC monotherapy in patients with progressive metastatic castration-resistant prostate cancer following abiraterone and/or enzalutamide: Efficacy and safety in open-label single-arm phase 2 study. Prostate. 2020 01; 80(1):99-108. PMID: 31742767.
      Citations:    
    207. De Vincentis G, Gerritsen W, Gschwend JE, Hacker M, Lewington V, O'Sullivan JM, Oya M, Pacilio M, Parker C, Shore N, Sartor O. Advances in targeted alpha therapy for prostate cancer. Ann Oncol. 2019 11 01; 30(11):1728-1739. PMID: 31418764.
      Citations:    
    208. Crawford ED, Twardowski PW, Concepcion RS, Hafron JM, Harris RG, Moul JW, Gordan LN, Petrylak DP, Atkinson SN, Boldt-Houle DM, Keane TE, Higano CS, Henderson RJ, Kader AK, Hussain MH, Shore ND. The Impact of Late Luteinizing Hormone-Releasing Hormone Agonist Dosing on Testosterone Suppression in Patients with Prostate Cancer: An Analysis of United States Clinical Data. J Urol. 2020 Apr; 203(4):743-750. PMID: 31580749.
      Citations:    
    209. Shore N, Zurth C, Fricke R, Gieschen H, Graudenz K, Koskinen M, Ploeger B, Moss J, Prien O, Borghesi G, Petrenciuc O, Tammela TL, Kuss I, Verholen F, Smith MR, Fizazi K. Evaluation of Clinically Relevant Drug-Drug Interactions and Population Pharmacokinetics of Darolutamide in Patients with Nonmetastatic Castration-Resistant Prostate Cancer: Results of Pre-Specified and Post Hoc Analyses of the Phase III ARAMIS Trial. Target Oncol. 2019 10; 14(5):527-539. PMID: 31571095.
      Citations:    
    210. Higano CS, Armstrong AJ, Sartor AO, Vogelzang NJ, Kantoff PW, McLeod DG, Pieczonka CM, Penson DF, Shore ND, Vacirca J, Concepcion RS, Tutrone RF, Nordquist LT, Quinn DI, Kassabian V, Scholz MC, Harmon M, Tyler RC, Chang NN, Tang H, Cooperberg MR. Real-world outcomes of sipuleucel-T treatment in PROCEED, a prospective registry of men with metastatic castration-resistant prostate cancer. Cancer. 2019 12 01; 125(23):4172-4180. PMID: 31483485.
      Citations:    
    211. Shore ND, Saltzstein D, Sieber P, Mehlhaff B, Gervasi L, Phillips J, Wong YN, Pei H, McGowan T. Results of a Real-world Study of Enzalutamide and Abiraterone Acetate With Prednisone Tolerability (REAAcT). Clin Genitourin Cancer. 2019 12; 17(6):457-463.e6. PMID: 31473120.
      Citations:    
    212. Armstrong AJ, Szmulewitz RZ, Petrylak DP, Holzbeierlein J, Villers A, Azad A, Alcaraz A, Alekseev B, Iguchi T, Shore ND, Rosbrook B, Sugg J, Baron B, Chen L, Stenzl A. ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer. J Clin Oncol. 2019 11 10; 37(32):2974-2986. PMID: 31329516.
      Citations:    
    213. Shelton JB, Shore N. AUTHOR REPLY. Urology. 2019 07; 129:86. PMID: 31235007.
      Citations:    
    214. Weiner AB, Manjunath A, Kirsh GM, Scott JA, Concepcion RD, Verniero J, Kapoor DA, Shore ND, Schaeffer EM. The Cost of Prostate Biopsies and their Complications: A Summary of Data on All Medicare Fee-for-Service Patients over 2 Years. Urol Pract. 2020 Mar; 7(2):145-151. PMID: 37317377.
      Citations:    
    215. Konety B, Shore N, Kader AK, Porten S, Daneshmand S, Lough T, Lotan Y. Evaluation of Cxbladder and Adjudication of Atypical Cytology and Equivocal Cystoscopy. Eur Urol. 2019 08; 76(2):238-243. PMID: 31103391.
      Citations:    
    216. Meng MV, Gschwend JE, Shore N, Grossfeld GD, Mostafid H, Black PC. Emerging Immunotherapy Options for bacillus Calmette-Gu?rin Unresponsive Nonmuscle Invasive Bladder Cancer. J Urol. 2019 12; 202(6):1111-1119. PMID: 31042108.
      Citations:    
    217. Holl EK, McNamara MA, Healy P, Anand M, Concepcion RS, Breland CD, Dumbudze I, Tutrone R, Shore N, Armstrong AJ, Harrison M, Wallace JA, Wu Y, George DJ. Prolonged PSA stabilization and overall survival following sipuleucel-T monotherapy in metastatic castration-resistant prostate cancer patients. Prostate Cancer Prostatic Dis. 2019 12; 22(4):588-592. PMID: 30980027.
      Citations:    
    218. Shelton JB, Buffington P, Augspurger R, Gaylis F, Cohen T, Mehlhaff B, Suh R, Bradford TJ, Kwan L, Koo AS, Shore N. Contemporary Management of Incident Prostate Cancer in Large Community Urology Practices in the United States. Urology. 2019 07; 129:79-86. PMID: 30954610.
      Citations:    
    219. Shore N, Mincik I, DeGuenther M, Student V, Jievaltas M, Patockova J, Simpson K, Hu CH, Huang ST, Li Y, Lee Y, Chien B, Mao J. A phase 3, open-label, multicenter study of a 6-month pre-mixed depot formulation of leuprolide mesylate in advanced prostate cancer patients. World J Urol. 2020 Jan; 38(1):111-119. PMID: 30941562.
      Citations:    
    220. Crawford ED, Koo PJ, Shore N, Slovin SF, Concepcion RS, Freedland SJ, Gomella LG, Karsh L, Keane TE, Maroni P, Penson D, Petrylak DP, Ross A, Mouraviev V, Reiter RE, Divgi C, Yu EY. A Clinician's Guide to Next Generation Imaging in Patients With Advanced Prostate Cancer (RADAR III). J Urol. 2019 04; 201(4):682-692. PMID: 30077557.
      Citations:    
    221. Gulley JL, Borre M, Vogelzang NJ, Ng S, Agarwal N, Parker CC, Pook DW, Rathenborg P, Flaig TW, Carles J, Saad F, Shore ND, Chen L, Heery CR, Gerritsen WR, Priou F, Langkilde NC, Novikov A, Kantoff PW. Phase III Trial of PROSTVAC in Asymptomatic or Minimally Symptomatic Metastatic Castration-Resistant Prostate Cancer. J Clin Oncol. 2019 05 01; 37(13):1051-1061. PMID: 30817251.
      Citations:    
    222. Fizazi K, Shore N, Tammela TL, Ulys A, Vjaters E, Polyakov S, Jievaltas M, Luz M, Alekseev B, Kuss I, Kappeler C, Snapir A, Sarapohja T, Smith MR. Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer. N Engl J Med. 2019 03 28; 380(13):1235-1246. PMID: 30763142.
      Citations:    
    223. Shore ND, Guerrero S, Sanahuja RM, Gamb?s G, Parente A. A New Sustained-release, 3-Month Leuprolide Acetate?Formulation Achieves and Maintains Castrate Concentrations of Testosterone in Patients With Prostate Cancer. Clin Ther. 2019 03; 41(3):412-425. PMID: 30929678.
      Citations:    
    224. Petrylak DP, Kantoff P, Vogelzang NJ, Mega A, Fleming MT, Stephenson JJ, Frank R, Shore ND, Dreicer R, McClay EF, Berry WR, Agarwal M, DiPippo VA, Rotshteyn Y, Stambler N, Olson WC, Morris SA, Israel RJ. Phase 1 study of PSMA ADC, an antibody-drug conjugate targeting prostate-specific membrane antigen, in chemotherapy-refractory prostate cancer. Prostate. 2019 05; 79(6):604-613. PMID: 30663074.
      Citations:    
    225. Shore N, Tutrone R, Roehrborn CG. Efficacy and safety of fexapotide triflutate in outpatient medical treatment of male lower urinary tract symptoms associated with benign prostatic hyperplasia. Ther Adv Urol. 2019 Jan-Dec; 11:1756287218820807. PMID: 30719081.
      Citations:    
    226. Crawford ED, Tombal B, Keane T, Boccardo F, Miller K, Shore N, Moul JW, Damber JE, Collette L, Persson BE. FSH suppression and tumour control in patients with prostate cancer during androgen deprivation with a GnRH agonist or antagonist. Scand J Urol. 2018 Oct - Dec; 52(5-6):349-357. PMID: 30624128.
      Citations:    
    227. Shore ND, Kapoor DA, Goldfischer ER, Chaikin DC, Walz EL, Henderson RJ, Harris RG, Asinof RD, Kirsh GM. Preserving Independent Urology: LUGPA's First Decade. Rev Urol. 2019; 21(2-3):102-108. PMID: 31768137.
      Citations:    
    228. Concepcion RS, Schaeffer EM, Shore ND, Kapoor DA, Scott JA, Kirsh GM. The Effect of Local Antibiogram-based Augmented Antibiotic Prophylaxis on Infection-related Complications Following Prostate Biopsy. Rev Urol. 2019; 21(2-3):93-101. PMID: 31768136.
      Citations:    
    229. Williams SB, Ray-Zack MD, Hudgins HK, Oldenburg J, Trinh QD, Nguyen PL, Shore ND, Wirth MP, O'Brien T, Catto JWF. Impact of Centralizing Care for Genitourinary Malignancies to High-volume Providers: A Systematic Review. Eur Urol Oncol. 2019 05; 2(3):265-273. PMID: 31200840.
      Citations:    
    230. Shore N, Hafron J, Langford T, Stein M, DeHart J, Brawer M, Hessels D, Schalken J, Van Criekinge W, Groskopf J, Wojno K. Urinary Molecular Biomarker Test Impacts Prostate Biopsy Decision Making in Clinical Practice. Urol Pract. 2019 Jul; 6(4):256-261. PMID: 37317474.
      Citations:    
    231. Schultz NM, Shore ND, Chowdhury S, Klotz LH, Concepcion RS, Penson DF, Karsh LI, Yang H, Brown BA, Barlev A, Flanders SC. Correction to: Number-needed-to-treat analysis of clinical progression in patients with metastatic castration-resistant prostate cancer in the STRIVE and TERRAIN trials. BMC Urol. 2018 10 01; 18(1):84. PMID: 30285696.
      Citations:    
    232. McKiernan J, Donovan MJ, Margolis E, Partin A, Carter B, Brown G, Torkler P, Noerholm M, Skog J, Shore N, Andriole G, Thompson I, Carroll P. A Prospective Adaptive Utility Trial to Validate Performance of a Novel Urine Exosome Gene Expression Assay to Predict High-grade Prostate Cancer in Patients with Prostate-specific Antigen 2-10ng/ml at Initial Biopsy. Eur Urol. 2018 12; 74(6):731-738. PMID: 30237023.
      Citations:    
    233. Schultz NM, Shore ND, Chowdhury S, Klotz LH, Concepcion RS, Penson DF, Karsh LI, Yang H, Brown BA, Barlev A, Flanders SC. Number-needed-to-treat analysis of clinical progression in patients with metastatic castration-resistant prostate cancer in the STRIVE and TERRAIN trials. BMC Urol. 2018 Sep 06; 18(1):77. PMID: 30189902.
      Citations:    
    234. Mateo J, Fizazi K, Gillessen S, Heidenreich A, Perez-Lopez R, Oyen WJG, Shore N, Smith M, Sweeney C, Tombal B, Tomlins SA, de Bono JS. Managing Nonmetastatic Castration-resistant Prostate Cancer. Eur Urol. 2019 02; 75(2):285-293. PMID: 30119985.
      Citations:    
    235. Karsh L, Shore N, Soloway M, Bhat G, Reddy G, Leu SY, Witjes JA. Double-Blind, Randomized, Placebo-controlled Studies Evaluating Apaziquone (E09, Qapzola?) Intravesical Instillation Post Transurethral Resection of Bladder Tumors for the Treatment of Low-risk Non-Muscle Invasive Bladder Cancer. Bladder Cancer. 2018 Jul 30; 4(3):293-301. PMID: 30112440.
      Citations:    
    236. Gupta S, Nordquist LT, Fleming MT, Berry WR, Zhang J, Ervin SL, Eisner JR, Baskin-Bey ES, Shore ND. Phase I Study of Seviteronel, a Selective CYP17 Lyase and Androgen Receptor Inhibitor, in Men with Castration-Resistant Prostate Cancer. Clin Cancer Res. 2018 11 01; 24(21):5225-5232. PMID: 30012563.
      Citations:    
    237. Hussain M, Fizazi K, Saad F, Rathenborg P, Shore N, Ferreira U, Ivashchenko P, Demirhan E, Modelska K, Krivoshik A, Sternberg CN. Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer. N Engl J Med. 2018 Jun 28; 378(26):2465-2474. PMID: 29949494.
      Citations:    
    238. Crawford ED, Schellhammer PF, McLeod DG, Moul JW, Higano CS, Shore N, Denis L, Iversen P, Eisenberger MA, Labrie F. Androgen Receptor Targeted Treatments of Prostate Cancer: 35 Years of Progress with Antiandrogens. J Urol. 2018 11; 200(5):956-966. PMID: 29730201.
      Citations:    
    239. Ryan CJ, Crawford ED, Shore ND, Underwood W, Taplin ME, Londhe A, Francis PSJ, Phillips J, McGowan T, Kantoff PW. The IMAAGEN Study: Effect of Abiraterone Acetate and Prednisone on Prostate Specific Antigen and Radiographic Disease Progression in Patients with Nonmetastatic Castration Resistant Prostate Cancer. J Urol. 2018 08; 200(2):344-352. PMID: 29630978.
      Citations:    
    240. Sade JP, B?ez CAV, Greco M, Mart?nez CH, Avitia M??, Palazzo C, Toriz NH, Trujillo PIB, Bastos DA, Schutz FA, Bella S, Nogueira L, Shore ND. Optimizing the treatment of metastatic castration-resistant prostate cancer: a Latin America perspective. Med Oncol. 2018 Mar 19; 35(4):56. PMID: 29556815.
      Citations:    
    241. Flanders SC, Kim J, Wilson S, Braziunas J, Greenfield S, Billimek J, Lechpammer S, Lin DW, Karsh L, Quinn DI, Shevrin D, Shore ND, Symanowski JT, Penson DF. Validating the total illness burden index for prostate cancer (TIBI-CaP) in men with castration-resistant prostate cancer: data from TRUMPET. Future Oncol. 2018 Mar; 14(6):527-536. PMID: 29417827.
      Citations:    
    242. Cella D, Traina S, Li T, Johnson K, Ho KF, Molina A, Shore ND. Relationship between patient-reported outcomes and clinical outcomes in metastatic castration-resistant prostate cancer: post hoc analysis of COU-AA-301 and COU-AA-302. Ann Oncol. 2018 02 01; 29(2):392-397. PMID: 29237083.
      Citations:    
    243. Shore N, Tutrone R, Efros M, Bidair M, Wachs B, Kalota S, Freedman S, Bailen J, Levin R, Richardson S, Kaminetsky J, Snyder J, Shepard B, Goldberg K, Hay A, Gange S, Grunberger I. Fexapotide triflutate: results of long-term safety and efficacy trials of a novel injectable therapy for symptomatic prostate enlargement. World J Urol. 2018 May; 36(5):801-809. PMID: 29380128.
      Citations:    
    244. Albitar M, Ma W, Lund L, Shahbaba B, Uchio E, Feddersen S, Moylan D, Wojno K, Shore N. Prostatectomy-based validation of combined urine and plasma test for predicting high grade prostate cancer. Prostate. 2018 03; 78(4):294-299. PMID: 29315679.
      Citations:    
    245. Parker C, Heidenreich A, Nilsson S, Shore N. Current approaches to incorporation of radium-223 in clinical practice. Prostate Cancer Prostatic Dis. 2018 04; 21(1):37-47. PMID: 29298991.
      Citations:    
    246. Armstrong AJ, Antonarakis ES, Taplin ME, Kelly WK, Beltran H, Fizazi K, Dahut WL, Shore N, Slovin S, George D, Carducci MA, Corn P, Danila D, Dreicer R, Heath E, Rathkopf D, Liu G, Nanus D, Stein M, Smith MR, Sternberg C, Wilding G, Nelson PS, Halabi S, Kantoff P, Clarke NW, Evans CP, Heidenreich A, Mottet N, Gleave M, Morris MJ, Scher HI. Naming disease states for clinical utility in prostate cancer: a rose by any other name might not smell as sweet. Ann Oncol. 2018 01 01; 29(1):23-25. PMID: 29088323.
      Citations:    
    247. Shore ND. LUGPA Onsite and LUGPA Virtual Crossfire Programs Offer Novel Alternatives to Attending an Out-oftown LUGPA Meeting. Rev Urol. 2018; 20(1):26-27. PMID: 29942198.
      Citations:    
    248. Shore ND. LUGPA Celebrates Its 10th Anniversary at Its 2018 Annual Meeting. Rev Urol. 2018; 20(3):131-132. PMID: 30473639.
      Citations:    
    249. Giri VN, Knudsen KE, Kelly WK, Abida W, Andriole GL, Bangma CH, Bekelman JE, Benson MC, Blanco A, Burnett A, Catalona WJ, Cooney KA, Cooperberg M, Crawford DE, Den RB, Dicker AP, Eggener S, Fleshner N, Freedman ML, Hamdy FC, Hoffman-Censits J, Hurwitz MD, Hyatt C, Isaacs WB, Kane CJ, Kantoff P, Karnes RJ, Karsh LI, Klein EA, Lin DW, Loughlin KR, Lu-Yao G, Malkowicz SB, Mann MJ, Mark JR, McCue PA, Miner MM, Morgan T, Moul JW, Myers RE, Nielsen SM, Obeid E, Pavlovich CP, Peiper SC, Penson DF, Petrylak D, Pettaway CA, Pilarski R, Pinto PA, Poage W, Raj GV, Rebbeck TR, Robson ME, Rosenberg MT, Sandler H, Sartor O, Schaeffer E, Schwartz GF, Shahin MS, Shore ND, Shuch B, Soule HR, Tomlins SA, Trabulsi EJ, Uzzo R, Vander Griend DJ, Walsh PC, Weil CJ, Wender R, Gomella LG. Role of Genetic Testing for Inherited Prostate Cancer Risk: Philadelphia Prostate Cancer Consensus Conference 2017. J Clin Oncol. 2018 02 01; 36(4):414-424. PMID: 29236593.
      Citations:    
    250. Sartor O, Vogelzang NJ, Sweeney C, Fernandez DC, Almeida F, Iagaru A, Brown A, Smith MR, Agrawal M, Dicker AP, Garcia JA, Lutzky J, Wong YN, Petrenciuc O, Gratt J, Shore ND, Morris MJ. Radium-223 Safety, Efficacy, and Concurrent Use with Abiraterone or Enzalutamide: First U.S. Experience from an Expanded Access Program. Oncologist. 2018 02; 23(2):193-202. PMID: 29183960.
      Citations:    
    251. Karsh LI, Gross ET, Pieczonka CM, Aliotta PJ, Skomra CJ, Ponsky LE, Nieh PT, Han M, Hamstra DA, Shore ND. Absorbable Hydrogel Spacer Use in Prostate Radiotherapy: A Comprehensive Review of Phase 3 Clinical Trial Published Data. Urology. 2018 May; 115:39-44. PMID: 29174940.
      Citations:    
    252. Saltzstein D, Shore ND, Moul JW, Chu F, Concepcion R, de la Motte S, McLane JA, Atkinson S, Yang A, Crawford ED. Pharmacokinetic and pharmacodynamic comparison of subcutaneous versus intramuscular leuprolide acetate formulations in male subjects. Ther Adv Urol. 2018 Feb; 10(2):43-50. PMID: 29434672.
      Citations:    
    253. Shore ND, Tutrone RF, Mariados NF, Nordquist LT, Mehlhaff BA, Steere KJ, Harrelson SS. eRADicAte: A Prospective Evaluation Combining Radium-223 Dichloride and Abiraterone Acetate Plus Prednisone in Patients With Castration-Resistant Prostate Cancer. Clin Genitourin Cancer. 2018 04; 16(2):149-154. PMID: 29196208.
      Citations:    
    254. Shore ND. Editorial Commentary. Urol Pract. 2018 Jan; 5(1):23. PMID: 37300173.
      Citations:    
    255. Shore N, Heidenreich A, Saad F. Author Reply. Urology. 2017 11; 109:17-18. PMID: 28941943.
      Citations:    
    256. Rathkopf DE, Smith MR, Ryan CJ, Berry WR, Shore ND, Liu G, Higano CS, Alumkal JJ, Hauke R, Tutrone RF, Saleh M, Chow Maneval E, Thomas S, Ricci DS, Yu MK, de Boer CJ, Trinh A, Kheoh T, Bandekar R, Scher HI, Antonarakis ES. Androgen receptor mutations in patients with castration-resistant prostate cancer treated with apalutamide. Ann Oncol. 2017 Sep 01; 28(9):2264-2271. PMID: 28633425.
      Citations:    
    257. Shore ND, Boorjian SA, Canter DJ, Ogan K, Karsh LI, Downs TM, Gomella LG, Kamat AM, Lotan Y, Svatek RS, Bivalacqua TJ, Grubb RL, Krupski TL, Lerner SP, Woods ME, Inman BA, Milowsky MI, Boyd A, Treasure FP, Gregory G, Sawutz DG, Yla-Herttuala S, Parker NR, Dinney CPN. Intravesical rAd-IFNa/Syn3 for Patients With High-Grade, Bacillus Calmette-Guerin-Refractory or Relapsed Non-Muscle-Invasive Bladder Cancer: A Phase II Randomized Study. J Clin Oncol. 2017 Oct 20; 35(30):3410-3416. PMID: 28834453.
      Citations:    
    258. Siemens DR, Klotz L, Heidenreich A, Chowdhury S, Villers A, Baron B, van Os S, Hasabou N, Wang F, Lin P, Shore ND. Efficacy and Safety of Enzalutamide vs Bicalutamide in Younger and Older Patients with Metastatic Castration Resistant Prostate Cancer in the TERRAIN Trial. J Urol. 2018 01; 199(1):147-154. PMID: 28827103.
      Citations:    
    259. Shore N, Heidenreich A, Saad F. Predicting Response and Recognizing Resistance: Improving Outcomes in Patients With Castration-resistant Prostate Cancer. Urology. 2017 11; 109:6-18. PMID: 28797685.
      Citations:    
    260. Gillessen S, Attard G, Beer TM, Beltran H, Bossi A, Bristow R, Carver B, Castellano D, Chung BH, Clarke N, Daugaard G, Davis ID, de Bono J, Borges Dos Reis R, Drake CG, Eeles R, Efstathiou E, Evans CP, Fanti S, Feng F, Fizazi K, Frydenberg M, Gleave M, Halabi S, Heidenreich A, Higano CS, James N, Kantoff P, Kellokumpu-Lehtinen PL, Khauli RB, Kramer G, Logothetis C, Maluf F, Morgans AK, Morris MJ, Mottet N, Murthy V, Oh W, Ost P, Padhani AR, Parker C, Pritchard CC, Roach M, Rubin MA, Ryan C, Saad F, Sartor O, Scher H, Sella A, Shore N, Smith M, Soule H, Sternberg CN, Suzuki H, Sweeney C, Sydes MR, Tannock I, Tombal B, Valdagni R, Wiegel T, Omlin A. Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017. Eur Urol. 2018 02; 73(2):178-211. PMID: 28655541.
      Citations:    
    261. Roehrborn CG, Barkin J, Gange SN, Shore ND, Giddens JL, Bolton DM, Cowan BE, Cantwell AL, McVary KT, Te AE, Gholami SS, Moseley WG, Chin PT, Dowling WT, Freedman SJ, Incze PF, Coffield KS, Herron S, Rashid P, Rukstalis DB. Five year results of the prospective randomized controlled prostatic urethral L.I.F.T. study. Can J Urol. 2017 Jun; 24(3):8802-8813. PMID: 28646935.
      Citations:    
    262. Shore ND. Darolutamide (ODM-201) for the treatment of prostate cancer. Expert Opin Pharmacother. 2017 Jun; 18(9):945-952. PMID: 28490267.
      Citations:    
    263. Li TT, Shore ND, Mehra M, Todd MB, Saadi R, Leblay G, Aggarwal J, Griffiths RI. Impact of subsequent metastases on costs and medical resource use for prostate cancer patients initially diagnosed with localized disease. Cancer. 2017 Sep 15; 123(18):3591-3601. PMID: 28542732.
      Citations:    
    264. Crawford ED, Shore ND, Petrylak DP, Higano CS, Ryan CJ. Abiraterone acetate and prednisone in chemotherapy-na?ve prostate cancer patients: rationale, evidence and clinical utility. Ther Adv Med Oncol. 2017 May; 9(5):319-333. PMID: 28529549.
      Citations:    
    265. Crawford ED, Schally AV, Pinthus JH, Block NL, Rick FG, Garnick MB, Eckel RH, Keane TE, Shore ND, Dahdal DN, Beveridge TJR, Marshall DC. The potential role of follicle-stimulating hormone in the cardiovascular, metabolic, skeletal, and cognitive effects associated with androgen deprivation therapy. Urol Oncol. 2017 05; 35(5):183-191. PMID: 28325650.
      Citations:    
    266. Smith MR, Saad F, Rathkopf DE, Mulders PFA, de Bono JS, Small EJ, Shore ND, Fizazi K, Kheoh T, Li J, De Porre P, Todd MB, Yu MK, Ryan CJ. Clinical Outcomes from Androgen Signaling-directed Therapy after Treatment with Abiraterone Acetate and Prednisone in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302. Eur Urol. 2017 07; 72(1):10-13. PMID: 28314611.
      Citations:    
    267. Crawford ED, Petrylak DP, Shore N, Saad F, Slovin SF, Vogelzang NJ, Keane TE, Koo PJ, Gomella LG, O'Sullivan JM, Tombal B, Concepcion RS, Sieber P, Stone NN, Finkelstein SE, Yu EY. The Role of Therapeutic Layering in Optimizing Treatment for Patients With Castration-resistant Prostate Cancer (Prostate Cancer Radiographic Assessments for Detection of Advanced Recurrence II). Urology. 2017 Jun; 104:150-159. PMID: 28302580.
      Citations:    
    268. Rathkopf DE, Antonarakis ES, Shore ND, Tutrone RF, Alumkal JJ, Ryan CJ, Saleh M, Hauke RJ, Bandekar R, Maneval EC, de Boer CJ, Yu MK, Scher HI. Safety and Antitumor Activity of Apalutamide (ARN-509) in Metastatic Castration-Resistant Prostate Cancer with and without Prior Abiraterone Acetate and Prednisone. Clin Cancer Res. 2017 Jul 15; 23(14):3544-3551. PMID: 28213364.
      Citations:    
    269. Shore ND, Tammela TL, Massard C, Bono P, Aspegren J, Mustonen M, Fizazi K. Safety and Antitumour Activity of ODM-201 (BAY-1841788) in Chemotherapy-na?ve and CYP17 Inhibitor-na?ve Patients: Follow-up from the ARADES and ARAFOR Trials. Eur Urol Focus. 2018 07; 4(4):547-553. PMID: 28753851.
      Citations:    
    270. Armstrong AJ, Saad F, Dmuchowski C, Shore ND, Fizazi K, Hirmand M, Forer D, Scher HI, Bono J. Clinical outcomes and survival surrogacy studies of prostate-specific antigen declines following enzalutamide in men with metastatic castration-resistant prostate cancer previously treated with docetaxel. Cancer. 2017 Jun 15; 123(12):2303-2311. PMID: 28171710.
      Citations:    
    271. Shore ND. LUGPA news. Rev Urol. 2017; 19(2):119-121. PMID: 28959149.
      Citations:    
    272. Kapoor DA, Shore ND. Alternative payment models. Rev Urol. 2017; 19(3):198-199. PMID: 29302246.
      Citations:    
    273. Shore ND. LUGPA Enhances 2017 Membership Opportunities. Rev Urol. 2017; 19(1):44-45. PMID: 28522929.
      Citations:    
    274. Shore ND. Are You Developing an ABC: Advanced Bladder Cancer Clinic? Rev Urol. 2017; 19(4):246-247. PMID: 29472827.
      Citations:    
    275. Shore ND. Practice management for urology groups: LUGPA's Guidebook. Rev Urol. 2017; 19(3):164-168. PMID: 29302239.
      Citations:    
    276. Shore ND, Dinney C, Uzzo R. The society of urologic oncology clinical trials consortium: A brief history and overview. Rev Urol. 2017; 19(2):122-124. PMID: 28959150.
      Citations:    
    277. McNeel DG, Bander NH, Beer TM, Drake CG, Fong L, Harrelson S, Kantoff PW, Madan RA, Oh WK, Peace DJ, Petrylak DP, Porterfield H, Sartor O, Shore ND, Slovin SF, Stein MN, Vieweg J, Gulley JL. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of prostate carcinoma. J Immunother Cancer. 2016; 4:92. PMID: 28031820.
      Citations:    
    278. Roehrborn CG, Gange SN, Gittelman MC, Goldberg KA, Patel K, Shore ND, Levin RM, Rousseau M, Beahrs JR, Kaminetsky J, Cowan BE, Cantrill CH, Mynderse LA, Ulchaker JC, Larson TR, Dixon CM, McVary KT. Convective Thermal Therapy: Durable 2-Year Results of Randomized Controlled and Prospective Crossover Studies for Treatment of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia. J Urol. 2017 06; 197(6):1507-1516. PMID: 27993667.
      Citations:    
    279. Antonarakis ES, Kibel AS, Yu EY, Karsh LI, Elfiky A, Shore ND, Vogelzang NJ, Corman JM, Millard FE, Maher JC, Chang NN, DeVries T, Sheikh NA, Drake CG. Sequencing of Sipuleucel-T and Androgen Deprivation Therapy in Men with Hormone-Sensitive Biochemically Recurrent Prostate Cancer: A Phase II Randomized Trial. Clin Cancer Res. 2017 May 15; 23(10):2451-2459. PMID: 27836866.
      Citations:    
    280. Donin NM, Chamie K, Lenis AT, Pantuck AJ, Reddy M, Kivlin D, Holldack J, Pozzi R, Hakim G, Karsh LI, Lamm DL, Belkoff LH, Belldegrun AS, Holden S, Shore N. A phase 2 study of TMX-101, intravesical imiquimod, for the treatment of carcinoma in situ bladder cancer. Urol Oncol. 2017 02; 35(2):39.e1-39.e7. PMID: 28341495.
      Citations:    
    281. Penson DF, Lin DW, Karsh L, Quinn DI, Shevrin DH, Shore N, Symanowski JT, Brown B, Forer D, Wong EK, Flanders SC. Treatment registry for outcomes in patients with castration-resistant prostate cancer (TRUMPET): a methodology for real-world evidence and research. Future Oncol. 2016 Dec; 12(23):2689-2699. PMID: 27528114.
      Citations:    
    282. Heidenreich A, Chowdhury S, Klotz L, Siemens DR, Villers A, Ivanescu C, Holmstrom S, Baron B, Wang F, Lin P, Shore ND. Impact of Enzalutamide Compared with Bicalutamide on Quality of Life in Men with Metastatic Castration-resistant Prostate Cancer: Additional Analyses from the TERRAIN Randomised Clinical Trial. Eur Urol. 2017 04; 71(4):534-542. PMID: 27497762.
      Citations:    
    283. Crawford ED, Rosenberg MT, Partin AW, Cooperberg MR, Maccini M, Loeb S, Pettaway CA, Shore ND, Arangua P, Hoenemeyer J, Leveridge M, Leapman M, Pinto P, Thompson IM, Carroll P, Eastham J, Gomella L, Klein EA. An Approach Using PSA Levels of 1.5?ng/mL as the Cutoff for Prostate Cancer Screening in Primary Care. Urology. 2016 Oct; 96:116-120. PMID: 27450937.
      Citations:    
    284. de Bono JS, Smith MR, Saad F, Rathkopf DE, Mulders PFA, Small EJ, Shore ND, Fizazi K, De Porre P, Kheoh T, Li J, Todd MB, Ryan CJ, Flaig TW. Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302. Eur Urol. 2017 04; 71(4):656-664. PMID: 27402060.
      Citations:    
    285. Smith MR, Antonarakis ES, Ryan CJ, Berry WR, Shore ND, Liu G, Alumkal JJ, Higano CS, Chow Maneval E, Bandekar R, de Boer CJ, Yu MK, Rathkopf DE. Phase 2 Study of the Safety and Antitumor Activity of Apalutamide (ARN-509), a Potent Androgen Receptor Antagonist, in the High-risk Nonmetastatic Castration-resistant Prostate Cancer Cohort. Eur Urol. 2016 12; 70(6):963-970. PMID: 27160947.
      Citations:    
    286. Gillessen S, Omlin A, Attard G, de Bono JS, Efstathiou E, Fizazi K, Halabi S, Nelson PS, Sartor O, Smith MR, Soule HR, Akaza H, Beer TM, Beltran H, Chinnaiyan AM, Daugaard G, Davis ID, De Santis M, Drake CG, Eeles RA, Fanti S, Gleave ME, Heidenreich A, Hussain M, James ND, Lecouvet FE, Logothetis CJ, Mastris K, Nilsson S, Oh WK, Olmos D, Padhani AR, Parker C, Rubin MA, Schalken JA, Scher HI, Sella A, Shore ND, Small EJ, Sternberg CN, Suzuki H, Sweeney CJ, Tannock IF, Tombal B. Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015. Ann Oncol. 2019 12; 30(12):e3. PMID: 27141017.
      Citations:    
    287. Lipton A, Smith MR, Fizazi K, Stopeck AT, Henry D, Brown JE, Shore ND, Saad F, Spencer A, Zhu L, Warner DJ. Changes in Bone Turnover Marker Levels and Clinical Outcomes in Patients with Advanced Cancer and Bone Metastases Treated with Bone Antiresorptive Agents. Clin Cancer Res. 2016 Dec 01; 22(23):5713-5721. PMID: 27140926.
      Citations:    
    288. Shore ND, Chu F, Moul J, Saltzstein D, Concepcion R, McLane JA, Atkinson S, Yang A, Crawford ED. Polymer-delivered subcutaneous leuprolide acetate formulations achieve and maintain castrate concentrations of testosterone in four open-label studies in patients with advanced prostate cancer. BJU Int. 2017 Feb; 119(2):239-244. PMID: 26991743.
      Citations:    
    289. Shore ND. Highlights in Metastatic Prostate Cancer From the 2016 American Society of Clinical Oncology Genitourinary Cancers Symposium: Commentary. Clin Adv Hematol Oncol. 2016 Apr; 14(4 Suppl 5):17-9. PMID: 27167847.
      Citations:    
    290. Fizazi K, Chi KN, de Bono JS, Gomella LG, Miller K, Rathkopf DE, Ryan CJ, Scher HI, Shore ND, De Porre P, Londhe A, McGowan T, Pelhivanov N, Charnas R, Todd MB, Montgomery B. Low Incidence of Corticosteroid-associated Adverse Events on Long-term Exposure to Low-dose Prednisone Given with Abiraterone Acetate to Patients with Metastatic Castration-resistant Prostate Cancer. Eur Urol. 2016 09; 70(3):438-44. PMID: 26965562.
      Citations:    
    291. Shore ND, Chowdhury S, Villers A, Klotz L, Siemens DR, van Os S, Hasabou N, Wang F, Bhattacharya S, Heidenreich A. Efficacy and safety of enzalutamide versus bicalutamide for patients with metastatic prostate cancer (TERRAIN): a randomised, double-blind, phase 2 study. Lancet Oncol. 2016 Feb; 17(2):153-163. PMID: 26774508.
      Citations:    
    292. Shore ND, Jacoby D. Urology Group Compensation and Ancillary Service Models in an Era of Value-based Care. Rev Urol. 2016; 18(3):143-150. PMID: 27833464.
      Citations:    
    293. Crawford ED, Albala DM, Wysocki JS, Lepor H, Ross AE, Finkelstein SE, Keane T, Freedland S, Harris R, Shore ND, Ryan CJ. Prostate Cancer Academy 2016: Presentation summaries. Rev Urol. 2016; 18(4):205-213. PMID: 28127262.
      Citations:    
    294. Stopeck AT, Fizazi K, Body JJ, Brown JE, Carducci M, Diel I, Fujiwara Y, Mart?n M, Paterson A, Tonkin K, Shore N, Sieber P, Kueppers F, Karsh L, Yardley D, Wang H, Maniar T, Arellano J, Braun A. Erratum to: Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer. Support Care Cancer. 2016 01; 24(1):457-458. PMID: 26482379.
      Citations:    
    295. Shore ND. When to initiate treatment with radium-223 in patients with metastatic castration-resistant prostate cancer. Clin Adv Hematol Oncol. 2016 Jan; 14(1):26-9. PMID: 27057663.
      Citations:    
    296. Shore ND. Looking ahead to 2017. Rev Urol. 2016; 18(4):225. PMID: 28127264.
      Citations:    
    297. Lipton A, Fizazi K, Stopeck AT, Henry DH, Smith MR, Shore N, Martin M, Vadhan-Raj S, Brown JE, Richardson GE, Saad F, Yardley DA, Zhou K, Balakumaran A, Braun A. Effect of denosumab versus zoledronic acid in preventing skeletal-related events in patients with bone metastases by baseline characteristics. Eur J Cancer. 2016 Jan; 53:75-83. PMID: 26693901.
      Citations:    
    298. Crawford ED, Petrylak DP, Higano CS, Kibel AS, Kantoff PW, Small EJ, Shore ND, Ferrari A. Optimal timing of sipuleucel-T treatment in metastatic castration-resistant prostate cancer. Can J Urol. 2015 Dec; 22(6):8048-55. PMID: 26688132.
      Citations:    
    299. Shore ND, Kella N, Moran B, Boczko J, Bianco FJ, Crawford ED, Davis T, Roundy KM, Rushton K, Grier C, Kaldate R, Brawer MK, Gonzalgo ML. Impact of the Cell Cycle Progression Test on Physician and Patient Treatment Selection for Localized Prostate Cancer. J Urol. 2016 Mar; 195(3):612-8. PMID: 26403586.
      Citations:    
    300. Stopeck AT, Fizazi K, Body JJ, Brown JE, Carducci M, Diel I, Fujiwara Y, Mart?n M, Paterson A, Tonkin K, Shore N, Sieber P, Kueppers F, Karsh L, Yardley D, Wang H, Maniar T, Arellano J, Braun A. Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer. Support Care Cancer. 2016 Jan; 24(1):447-455. PMID: 26335402.
      Citations:    
    301. Crawford ED, Higano CS, Shore ND, Hussain M, Petrylak DP. Treating Patients with Metastatic Castration Resistant Prostate Cancer: A Comprehensive Review of Available Therapies. J Urol. 2015 Dec; 194(6):1537-47. PMID: 26196735.
      Citations:    
    302. Gillessen S, Omlin A, Attard G, de Bono JS, Efstathiou E, Fizazi K, Halabi S, Nelson PS, Sartor O, Smith MR, Soule HR, Akaza H, Beer TM, Beltran H, Chinnaiyan AM, Daugaard G, Davis ID, De Santis M, Drake CG, Eeles RA, Fanti S, Gleave ME, Heidenreich A, Hussain M, James ND, Lecouvet FE, Logothetis CJ, Mastris K, Nilsson S, Oh WK, Olmos D, Padhani AR, Parker C, Rubin MA, Schalken JA, Scher HI, Sella A, Shore ND, Small EJ, Sternberg CN, Suzuki H, Sweeney CJ, Tannock IF, Tombal B. Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015. Ann Oncol. 2015 Aug; 26(8):1589-604. PMID: 26041764.
      Citations:    
    303. Roehrborn CG, Rukstalis DB, Barkin J, Gange SN, Shore ND, Giddens JL, Bolton DM, Cowan BE, Cantwell AL, McVary KT, Te AE, Gholami SS, Moseley WG, Chin PT, Dowling WT, Freedman SJ, Incze PF, Coffield KS, Borges FD, Rashid P. Three year results of the prostatic urethral L.I.F.T. study. Can J Urol. 2015 Jun; 22(3):7772-82. PMID: 26068624.
      Citations:    
    304. Shore ND. Advances in the understanding of cancer immunotherapy. BJU Int. 2015 Sep; 116(3):321-9. PMID: 24612369.
      Citations:    
    305. Saad F, Shore N, Van Poppel H, Rathkopf DE, Smith MR, de Bono JS, Logothetis CJ, de Souza P, Fizazi K, Mulders PF, Mainwaring P, Hainsworth JD, Beer TM, North S, Fradet Y, Griffin TA, De Porre P, Londhe A, Kheoh T, Small EJ, Scher HI, Molina A, Ryan CJ. Impact of bone-targeted therapies in chemotherapy-na?ve metastatic castration-resistant prostate cancer patients treated with abiraterone acetate: post hoc analysis of study COU-AA-302. Eur Urol. 2015 Oct; 68(4):570-7. PMID: 25985882.
      Citations:    
    306. Small EJ, Lance RS, Gardner TA, Karsh LI, Fong L, McCoy C, DeVries T, Sheikh NA, GuhaThakurta D, Chang N, Redfern CH, Shore ND. A Randomized Phase II Trial of Sipuleucel-T with Concurrent versus Sequential Abiraterone Acetate plus Prednisone in Metastatic Castration-Resistant Prostate Cancer. Clin Cancer Res. 2015 Sep 01; 21(17):3862-9. PMID: 25925891.
      Citations:    
    307. Joshua AM, Shore ND, Saad F, Chi KN, Olsson CA, Emmenegger U, Scholz M, Berry W, Mukherjee SD, Winquist E, Haas NB, Foley MA, Dmuchowski C, Perabo F, Hirmand M, Hasabou N, Rathkopf D. Safety of enzalutamide in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel: expanded access in North America. Prostate. 2015 Jun; 75(8):836-44. PMID: 25683285.
      Citations:    
    308. Shore ND. Radium-223 dichloride for metastatic castration-resistant prostate cancer: the urologist's perspective. Urology. 2015 Apr; 85(4):717-24. PMID: 25681834.
      Citations:    
    309. Shore ND, Karsh L, Gomella LG, Keane TE, Concepcion RS, Crawford ED. Avoiding obsolescence in advanced prostate cancer management: a guide for urologists. BJU Int. 2015 Feb; 115(2):188-97. PMID: 25756134.
      Citations:    
    310. Ryan CJ, Smith MR, Fizazi K, Saad F, Mulders PF, Sternberg CN, Miller K, Logothetis CJ, Shore ND, Small EJ, Carles J, Flaig TW, Taplin ME, Higano CS, de Souza P, de Bono JS, Griffin TW, De Porre P, Yu MK, Park YC, Li J, Kheoh T, Naini V, Molina A, Rathkopf DE. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2015 Feb; 16(2):152-60. PMID: 25601341.
      Citations:    
    311. Quinn DI, Shore ND, Egawa S, Gerritsen WR, Fizazi K. Immunotherapy for castration-resistant prostate cancer: Progress and new paradigms. Urol Oncol. 2015 May; 33(5):245-60. PMID: 25575714.
      Citations:    
    312. Shore ND. Thriving in the Independent Setting: Highlights From the 2014 LUGPA Annual Meeting. Rev Urol. 2015; 17(1):31-2. PMID: 26028999.
      Citations:    
    313. Shore N. A Review of the Prostatic Urethral Lift for Lower Urinary Tract Symptoms: Symptom Relief, Flow Improvement, and Preservation of Sexual Function in Men With Benign Prostatic Hyperplasia. Curr Bladder Dysfunct Rep. 2015; 10(2):186-192. PMID: 25984251.
      Citations:    
    314. Shore ND. LUGPA Welcomes Membership of Smaller Practices. Rev Urol. 2015; 17(2):86-7. PMID: 27222645.
      Citations:    
    315. Crawford ED, Moul JW, Sartor O, Shore ND. Extended release, 6-month formulations of leuprolide acetate for the treatment of advanced prostate cancer: achieving testosterone levels below 20 ng/dl. Expert Opin Drug Metab Toxicol. 2015; 11(9):1465-74. PMID: 26293510.
      Citations:    
    316. Shore N. Management of early-stage prostate cancer. Am J Manag Care. 2014 Dec; 20(12 Suppl):S260-72. PMID: 25734965.
      Citations:    
    317. Sur RL, Shore N, L'Esperance J, Knudsen B, Gupta M, Olsen S, Shah O. Silodosin to facilitate passage of ureteral stones: a multi-institutional, randomized, double-blinded, placebo-controlled trial. Eur Urol. 2015 May; 67(5):959-64. PMID: 25465978.
      Citations:    
    318. Fizazi K, Massard C, Smith M, Rader M, Brown J, Milecki P, Shore N, Oudard S, Karsh L, Carducci M, Dami?o R, Wang H, Ying W, Goessl C. Bone-related Parameters are the Main Prognostic Factors for Overall Survival in Men with Bone Metastases from Castration-resistant Prostate Cancer. Eur Urol. 2015 Jul; 68(1):42-50. PMID: 25449207.
      Citations:    
    319. Parekh DJ, Punnen S, Sjoberg DD, Asroff SW, Bailen JL, Cochran JS, Concepcion R, David RD, Deck KB, Dumbadze I, Gambla M, Grable MS, Henderson RJ, Karsh L, Krisch EB, Langford TD, Lin DW, McGee SM, Munoz JJ, Pieczonka CM, Rieger-Christ K, Saltzstein DR, Scott JW, Shore ND, Sieber PR, Waldmann TM, Wolk FN, Zappala SM. A multi-institutional prospective trial in the USA confirms that the 4Kscore accurately identifies men with high-grade prostate cancer. Eur Urol. 2015 Sep; 68(3):464-70. PMID: 25454615.
      Citations:    
    320. Finkelstein SE, Salenius S, Mantz CA, Shore ND, Fernandez EB, Shulman J, Myslicki FA, Agassi AM, Rotterman Y, DeVries T, Sims R. Combining immunotherapy and radiation for prostate cancer. Clin Genitourin Cancer. 2015 Feb; 13(1):1-9. PMID: 25450032.
      Citations:    
    321. Roehrborn CG, Gange SN, Shore ND, Giddens JL, Bolton DM, Cowan BE, Cantwell AL, McVary KT, Te AE, Gholami SS, Rashid P, Moseley WG, Chin PT, Dowling WT, Freedman SJ, Incze PF, Coffield KS, Borges FD, Rukstalis DB. Durability of the Prostatic Urethral Lift: 2-Year Results of the L.I.F.T. Study. Urol Pract. 2015 01; 2(1):26-32. PMID: 37537806.
      Citations:    
    322. Saad F, de Bono J, Shore N, Fizazi K, Loriot Y, Hirmand M, Franks B, Haas GP, Scher HI. Efficacy outcomes by baseline prostate-specific antigen quartile in the AFFIRM trial. Eur Urol. 2015 Feb; 67(2):223-30. PMID: 25171902.
      Citations:    
    323. Shore N. Management of advanced prostate cancer - role of the urologist. Curr Urol Rep. 2014 Jul; 15(7):419. PMID: 24817261.
      Citations:    
    324. Padhi D, Higano CS, Shore ND, Sieber P, Rasmussen E, Smith MR. Pharmacological inhibition of myostatin and changes in lean body mass and lower extremity muscle size in patients receiving androgen deprivation therapy for prostate cancer. J Clin Endocrinol Metab. 2014 Oct; 99(10):E1967-75. PMID: 24971661.
      Citations:    
    325. Crawford ED, Shore ND, Moul JW, Tombal B, Schr?der FH, Miller K, Boccon-Gibod L, Malmberg A, Olesen TK, Persson BE, Klotz L. Long-term tolerability and efficacy of degarelix: 5-year results from a phase III extension trial with a 1-arm crossover from leuprolide to degarelix. Urology. 2014 May; 83(5):1122-8. PMID: 24661333.
      Citations:    
    326. Rathkopf DE, Smith MR, de Bono JS, Logothetis CJ, Shore ND, de Souza P, Fizazi K, Mulders PF, Mainwaring P, Hainsworth JD, Beer TM, North S, Fradet Y, Van Poppel H, Carles J, Flaig TW, Efstathiou E, Yu EY, Higano CS, Taplin ME, Griffin TW, Todd MB, Yu MK, Park YC, Kheoh T, Small EJ, Scher HI, Molina A, Ryan CJ, Saad F. Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302). Eur Urol. 2014 Nov; 66(5):815-25. PMID: 24647231.
      Citations:    
    327. Shore ND, Cookson MS. Proper Sequencing of Treatment for Castrate Resistant Prostate Cancer. Urol Pract. 2014 May; 1(1):2-6. PMID: 37533220.
      Citations:    
    328. Ma W, Diep K, Fritsche HA, Shore N, Albitar M. Diagnostic and prognostic scoring system for prostate cancer using urine and plasma biomarkers. Genet Test Mol Biomarkers. 2014 Mar; 18(3):156-63. PMID: 24512523.
      Citations:    
    329. Shore N, Freedman S, Gange S, Moseley W, Heron S, Tutrone R, Brown T, Barkin J. Prospective multi-center study elucidating patient experience after prostatic urethral lift. Can J Urol. 2014 Feb; 21(1):7094-101. PMID: 24529008.
      Citations:    
    330. Klotz L, Miller K, Crawford ED, Shore N, Tombal B, Karup C, Malmberg A, Persson BE. Disease control outcomes from analysis of pooled individual patient data from five comparative randomised clinical trials of degarelix versus luteinising hormone-releasing hormone agonists. Eur Urol. 2014 Dec; 66(6):1101-8. PMID: 24440304.
      Citations:    
    331. Crawford ED, Stone NN, Yu EY, Koo PJ, Freedland SJ, Slovin SF, Gomella LG, Berger ER, Keane TE, Sieber P, Shore ND, Petrylak DP. Challenges and recommendations for early identification of metastatic disease in prostate cancer. Urology. 2014 Mar; 83(3):664-9. PMID: 24411213.
      Citations:    
    332. Mouraviev V, Mariados N, Albala D, Concepcion RS, Shore ND, Sims RB, Emberton M, Pieczonka CM. The Rationale for Optimal Combination Therapy With Sipuleucel-T for Patients With Castration-resistant Prostate Cancer. Rev Urol. 2014; 16(3):122-30. PMID: 25337042.
      Citations:    
    333. Shore ND. PROSTVAC? targeted immunotherapy candidate for prostate cancer. Immunotherapy. 2014; 6(3):235-47. PMID: 24762070.
      Citations:    
    334. Quinn DI, Vaishampayan U, Higano CS, Lin DW, Shore ND, Beer TM. Sequencing therapy in advanced prostate cancer: focus on sipuleucel-T. Expert Rev Anticancer Ther. 2014 Jan; 14(1):51-61. PMID: 24224900.
      Citations:    
    335. Shore N, Concepcion R, Saltzstein D, Lucia MS, van Breda A, Welbourn W, Lewine N, Gustavsen G, Pothier K, Brawer MK. Clinical utility of a biopsy-based cell cycle gene expression assay in localized prostate cancer. Curr Med Res Opin. 2014 Apr; 30(4):547-53. PMID: 24320750.
      Citations:    
    336. Ryan C, Shore ND, Concepcion R. A urologic oncology roundtable discussion: how to choose among the available therapies for the treatment of castration-resistant prostate cancer. Postgrad Med. 2013 Nov; 125(6):114-6. PMID: 24200767.
      Citations:    
    337. Rothschild J, Thompson IM, Concepcion RS, Shore ND. Infusion therapy and implantables for the urologist. Urol Clin North Am. 2013 Nov; 40(4):591-8. PMID: 24182978.
      Citations:    
    338. Shore ND. The success of therapies for metastatic CRPC continues. Oncology (Williston Park). 2013 Nov; 27(11):1160-1. PMID: 24575545.
      Citations:    
    339. Shore ND, Concepcion R, Barocas DA. A urologic oncology roundtable discussion: the role of disease monitoring in treatment decision-making for patients with metastatic castration-resistant prostate cancer. Hosp Pract (1995). 2013 Oct-Nov; 41(4):78-80. PMID: 24145592.
      Citations:    
    340. Basch E, Autio K, Ryan CJ, Mulders P, Shore N, Kheoh T, Fizazi K, Logothetis CJ, Rathkopf D, Smith MR, Mainwaring PN, Hao Y, Griffin T, Li S, Meyers ML, Molina A, Cleeland C. Abiraterone acetate plus prednisone versus prednisone alone in chemotherapy-naive men with metastatic castration-resistant prostate cancer: patient-reported outcome results of a randomised phase 3 trial. Lancet Oncol. 2013 Nov; 14(12):1193-9. PMID: 24075621.
      Citations:    
    341. Smith MR, Saad F, Oudard S, Shore N, Fizazi K, Sieber P, Tombal B, Damiao R, Marx G, Miller K, Van Veldhuizen P, Morote J, Ye Z, Dansey R, Goessl C. Denosumab and bone metastasis-free survival in men with nonmetastatic castration-resistant prostate cancer: exploratory analyses by baseline prostate-specific antigen doubling time. J Clin Oncol. 2013 Oct 20; 31(30):3800-6. PMID: 24043751.
      Citations:    
    342. Shore ND. Experience with degarelix in the treatment of prostate cancer. Ther Adv Urol. 2013 Feb; 5(1):11-24. PMID: 23372607.
      Citations:    
    343. Shore ND, Mantz CA, Dosoretz DE, Fernandez E, Myslicki FA, McCoy C, Finkelstein SE, Fishman MN. Building on sipuleucel-T for immunologic treatment of castration-resistant prostate cancer. Cancer Control. 2013 Jan; 20(1):7-16. PMID: 23302902.
      Citations:    
    344. Shore ND, Fernandez CA, Shuber AP. Noninvasive multianalyte diagnostic assay for monitoring bladder cancer recurrence. Res Rep Urol. 2012; 4:49-56. PMID: 24199181.
      Citations:    
    345. Staskin DR, Peters KM, MacDiarmid S, Shore N, de Groat WC. Percutaneous tibial nerve stimulation: a clinically and cost effective addition to the overactive bladder algorithm of care. Curr Urol Rep. 2012 Oct; 13(5):327-34. PMID: 22893501.
      Citations:    
    346. Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, de Wit R, Mulders P, Chi KN, Shore ND, Armstrong AJ, Flaig TW, Fl?chon A, Mainwaring P, Fleming M, Hainsworth JD, Hirmand M, Selby B, Seely L, de Bono JS. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012 Sep 27; 367(13):1187-97. PMID: 22894553.
      Citations:    
    347. Shore ND. Highlights in advanced prostate cancer from the 2012 American Urological Association Annual Meeting and the 2012 American Society of Clinical Oncology Annual Meeting. Clin Adv Hematol Oncol. 2012 Aug; 10(8 Suppl 12):1-24. PMID: 23072827.
      Citations:    
    348. Nickel JC, Jain P, Shore N, Anderson J, Giesing D, Lee H, Kim G, Daniel K, White S, Larrivee-Elkins C, Lekstrom-Himes J, Cima M. Continuous intravesical lidocaine treatment for interstitial cystitis/bladder pain syndrome: safety and efficacy of a new drug delivery device. Sci Transl Med. 2012 Jul 18; 4(143):143ra100. PMID: 22814850.
      Citations:    
    349. Rove KO, Debruyne FM, Djavan B, Gomella LG, Koul HK, Lucia MS, Petrylak DP, Shore ND, Stone NN, Crawford ED. Role of testosterone in managing advanced prostate cancer. Urology. 2012 Oct; 80(4):754-62. PMID: 22795376.
      Citations:    
    350. Shore ND, Abrahamsson PA, Anderson J, Crawford ED, Lange P. New considerations for ADT in advanced prostate cancer and the emerging role of GnRH antagonists. Prostate Cancer Prostatic Dis. 2013 Mar; 16(1):7-15. PMID: 22751146.
      Citations:    
    351. Tolcher AW, Chi KN, Shore ND, Pili R, Molina A, Acharya M, Kheoh T, Jiao JJ, Gonzalez M, Trinh A, Pankras C, Tran N. Effect of abiraterone acetate plus prednisone on the QT interval in patients with metastatic castration-resistant prostate cancer. Cancer Chemother Pharmacol. 2012 Aug; 70(2):305-13. PMID: 22752297.
      Citations:    
    352. Shore ND. Chemotherapy for prostate cancer: when should a urologist refer a patient to a medical oncologist? Prostate Cancer Prostatic Dis. 2013 Mar; 16(1):1-6. PMID: 22751145.
      Citations:    
    353. Lin DW, Shore ND. The changing landscape of urologic oncology: initiating systemic therapies, interventional skills, and clinical trials. Introduction. Urol Oncol. 2012 Jul-Aug; 30(4 Suppl):S1. PMID: 22795074.
      Citations:    
    354. Freedland SJ, Richhariya A, Wang H, Chung K, Shore ND. Treatment patterns in patients with prostate cancer and bone metastasis among US community-based urology group practices. Urology. 2012 Aug; 80(2):293-8. PMID: 22748612.
      Citations:    
    355. Shore N, Mason M, de Reijke TM. New developments in castrate-resistant prostate cancer. BJU Int. 2012 Jun; 109 Suppl 6:22-32. PMID: 22672122.
      Citations:    
    356. Nielsen ME, Smith AB, Pruthi RS, Guzzo TJ, Amiel G, Shore N, Lotan Y. Reported use of intravesical therapy for non-muscle-invasive bladder cancer (NMIBC): results from the Bladder Cancer Advocacy Network (BCAN) survey. BJU Int. 2012 Oct; 110(7):967-72. PMID: 22487336.
      Citations:    
    357. Djavan B, Eastham J, Gomella L, Tombal B, Taneja S, Dianat SS, Kazzazi A, Shore N, Abrahamsson PA, Cheetham P, Moul J, Lepor H, Crawford ED. Testosterone in prostate cancer: the Bethesda consensus. BJU Int. 2012 Aug; 110(3):344-52. PMID: 22129242.
      Citations:    
    358. Smith MR, Saad F, Coleman R, Shore N, Fizazi K, Tombal B, Miller K, Sieber P, Karsh L, Dami?o R, Tammela TL, Egerdie B, Van Poppel H, Chin J, Morote J, G?mez-Veiga F, Borkowski T, Ye Z, Kupic A, Dansey R, Goessl C. Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial. Lancet. 2012 Jan 07; 379(9810):39-46. PMID: 22093187.
      Citations:    
    359. Sonpavde G, Di Lorenzo G, Higano CS, Kantoff PW, Madan R, Shore ND. The role of sipuleucel-T in therapy for castration-resistant prostate cancer: a critical analysis of the literature. Eur Urol. 2012 Apr; 61(4):639-47. PMID: 22036643.
      Citations:    
    360. Saad F, Brown JE, Van Poznak C, Ibrahim T, Stemmer SM, Stopeck AT, Diel IJ, Takahashi S, Shore N, Henry DH, Barrios CH, Facon T, Senecal F, Fizazi K, Zhou L, Daniels A, Carri?re P, Dansey R. Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases. Ann Oncol. 2012 May; 23(5):1341-1347. PMID: 21986094.
      Citations:    
    361. Frenkl T, Railkar R, Shore N, Bailen J, Sutherland S, Burke J, Scott BB, Ruddy M, Beals C. Evaluation of an experimental urodynamic platform to identify treatment effects: a randomized, placebo-controlled, crossover study in patients with overactive bladder. Neurourol Urodyn. 2012 Jan; 31(1):69-74. PMID: 21905086.
      Citations:    
    362. Shore N, Cookson MS, Gittelman MC. Long-term efficacy and tolerability of once-yearly histrelin acetate subcutaneous implant in patients with advanced prostate cancer. BJU Int. 2012 Jan; 109(2):226-32. PMID: 21851539.
      Citations:    
    363. Zurita AJ, George DJ, Shore ND, Liu G, Wilding G, Hutson TE, Kozloff M, Mathew P, Harmon CS, Wang SL, Chen I, Chow Maneval E, Logothetis CJ. Sunitinib in combination with docetaxel and prednisone in chemotherapy-naive patients with metastatic, castration-resistant prostate cancer: a phase 1/2 clinical trial. Ann Oncol. 2012 Mar; 23(3):688-694. PMID: 21821830.
      Citations:    
    364. Shore ND. Phacilitate Barcelona active immunotherapeutics forum. 11-13 May 2011, Barcelona, Spain. Immunotherapy. 2011 Aug; 3(8):931-2. PMID: 21843080.
      Citations:    
    365. Crawford ED, Tombal B, Miller K, Boccon-Gibod L, Schr?der F, Shore N, Moul JW, Jensen JK, Olesen TK, Persson BE. A phase III extension trial with a 1-arm crossover from leuprolide to degarelix: comparison of gonadotropin-releasing hormone agonist and antagonist effect on prostate cancer. J Urol. 2011 Sep; 186(3):889-97. PMID: 21788033.
      Citations:    
    366. Fizazi K, Carducci M, Smith M, Dami?o R, Brown J, Karsh L, Milecki P, Shore N, Rader M, Wang H, Jiang Q, Tadros S, Dansey R, Goessl C. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet. 2011 Mar 05; 377(9768):813-22. PMID: 21353695.
      Citations:    
    367. Shore ND, Sethi PS. A controlled, randomized, head-to-head comparison of the Prolieve thermodilatation System versus the Targis System for benign prostatic hyperplasia: safety, procedural tolerability, and clinical results. J Endourol. 2010 Sep; 24(9):1469-75. PMID: 20677916.
      Citations:    
    368. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, Redfern CH, Ferrari AC, Dreicer R, Sims RB, Xu Y, Frohlich MW, Schellhammer PF. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010 Jul 29; 363(5):411-22. PMID: 20818862.
      Citations:    
    369. Gan TJ, Berry BD, Ekman EF, Muckerman RC, Shore N, Hardi R. Safety evaluation of fospropofol for sedation during minor surgical procedures. J Clin Anesth. 2010 Jun; 22(4):260-7. PMID: 20522356.
      Citations:    
    370. Marberger M, Kaisary AV, Shore ND, Karlin GS, Savulsky C, Mis R, Leuratti C, Germa JR. Effectiveness, pharmacokinetics, and safety of a new sustained-release leuprolide acetate 3.75-mg depot formulation for testosterone suppression in patients with prostate cancer: a Phase III, open-label, international multicenter study. Clin Ther. 2010 Apr; 32(4):744-57. PMID: 20435244.
      Citations:    
    371. Shore N. NX-1207: a novel investigational drug for the treatment of benign prostatic hyperplasia. Expert Opin Investig Drugs. 2010 Feb; 19(2):305-10. PMID: 20050813.
      Citations:    
    372. Shore ND, Crawford ED. Intermittent androgen deprivation therapy: redefining the standard of care? Rev Urol. 2010; 12(1):1-11. PMID: 20428288.
      Citations:    
    373. Tombal B, Miller K, Boccon-Gibod L, Schr?der F, Shore N, Crawford ED, Moul J, Jensen JK, Kold Olesen T, Persson BE. Additional analysis of the secondary end point of biochemical recurrence rate in a phase 3 trial (CS21) comparing degarelix 80 mg versus leuprolide in prostate cancer patients segmented by baseline characteristics. Eur Urol. 2010 May; 57(5):836-42. PMID: 19962227.
      Citations:    
    374. Schr?der FH, Tombal B, Miller K, Boccon-Gibod L, Shore ND, Crawford ED, Moul J, Olesen TK, Persson BE. Changes in alkaline phosphatase levels in patients with prostate cancer receiving degarelix or leuprolide: results from a 12-month, comparative, phase III study. BJU Int. 2010 Jul; 106(2):182-7. PMID: 19912212.
      Citations:    
    375. Lotan Y, Kamat AM, Porter MP, Robinson VL, Shore N, Jewett M, Schelhammer PF, deVere White R, Quale D, Lee CT. Key concerns about the current state of bladder cancer: a position paper from the Bladder Cancer Think Tank, the Bladder Cancer Advocacy Network, and the Society of Urologic Oncology. Cancer. 2009 Sep 15; 115(18):4096-103. PMID: 19536899.
      Citations:    
    376. Freedland SJ, Eastham J, Shore N. Androgen deprivation therapy and estrogen deficiency induced adverse effects in the treatment of prostate cancer. Prostate Cancer Prostatic Dis. 2009; 12(4):333-8. PMID: 19901933.
      Citations:    
    377. Klotz L, Boccon-Gibod L, Shore ND, Andreou C, Persson BE, Cantor P, Jensen JK, Olesen TK, Schr?der FH. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer. BJU Int. 2008 Dec; 102(11):1531-8. PMID: 19035858.
      Citations:    
    378. Shore ND, Dineen MK, Saslawsky MJ, Lumerman JH, Corica AP. A temporary intraurethral prostatic stent relieves prostatic obstruction following transurethral microwave thermotherapy. J Urol. 2007 Mar; 177(3):1040-6. PMID: 17296408.
      Citations:    
    379. Delk J, Knoll LD, McMurray J, Shore N, Wilson S. Early experience with the American Medical Systems new tactile pump: results of a multicenter study. J Sex Med. 2005 Mar; 2(2):266-71. PMID: 16422896.
      Citations:    
    380. Han KR, Cohen JK, Miller RJ, Pantuck AJ, Freitas DG, Cuevas CA, Kim HL, Lugg J, Childs SJ, Shuman B, Jayson MA, Shore ND, Moore Y, Zisman A, Lee JY, Ugarte R, Mynderse LA, Wilson TM, Sweat SD, Zincke H, Belldegrun AS. Treatment of organ confined prostate cancer with third generation cryosurgery: preliminary multicenter experience. J Urol. 2003 Oct; 170(4 Pt 1):1126-30. PMID: 14501706.
      Citations:    
    381. Mydlo JH, Shore N, Reuter V, Herr HW. Perirenal lipoma versus renal cell carcinoma. Urology. 1991 Jul; 38(1):67-9. PMID: 1866864.
      Citations:    
    382. Mydlo JH, Shore N, Herr HW. Renal cell metastases versus liver hemangioma. Urology. 1991 Mar; 37(3):257-9. PMID: 2000686.
      Citations:    
    383. Shore N, Somers W, Riehle RA. Evolution of pre-treatment stenting and local anesthesia for extracorporeal shock wave lithotripsy at a single university center. J Urol. 1990 Feb; 143(2):257-60. PMID: 2299714.
      Citations:    
    384. Shore ND, Bregg KJ, Sosa RE. Indwelling ureteral stents. Semin Urol. 1987 Aug; 5(3):200-7. PMID: 3310175.
      Citations:    
    385. Finklestein JZ, Shore N, Krivit W, Hammond D, Higgins G. Phase II trial of dianhydrogalactitol in the treatment of children with refractory childhood malignancies: a report from the Children's Cancer Study Group. Cancer Treat Rep. 1985 Nov; 69(11):1331-3. PMID: 4092198.
      Citations:    
    Shore's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (566)
    Explore
    _
    Co-Authors (21)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _